
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Original research: Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="322C300B24F3920500003F971061A145.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="jimmthercanc" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC10314633/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314633/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Journal for Immunotherapy of Cancer" /><meta name="citation_title" content="Original research: Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy" /><meta name="citation_author" content="Wenhui Shen" /><meta name="citation_author_institution" content="School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China" /><meta name="citation_author" content="Peishang Shi" /><meta name="citation_author_institution" content="School of Life Sciences, Zhengzhou University, Zhengzhou, China" /><meta name="citation_author" content="Qingyu Dong" /><meta name="citation_author_institution" content="School of Life Sciences, Zhengzhou University, Zhengzhou, China" /><meta name="citation_author" content="Xiuman Zhou" /><meta name="citation_author_institution" content="School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China" /><meta name="citation_author" content="Chunxia Chen" /><meta name="citation_author_institution" content="School of Life Sciences, Zhengzhou University, Zhengzhou, China" /><meta name="citation_author" content="Xinghua Sui" /><meta name="citation_author_institution" content="School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China" /><meta name="citation_author" content="Wentong Tian" /><meta name="citation_author_institution" content="School of Life Sciences, Zhengzhou University, Zhengzhou, China" /><meta name="citation_author" content="Xueqin Zhu" /><meta name="citation_author_institution" content="School of Life Sciences, Zhengzhou University, Zhengzhou, China" /><meta name="citation_author" content="Xiaoxi Wang" /><meta name="citation_author_institution" content="School of Life Sciences, Zhengzhou University, Zhengzhou, China" /><meta name="citation_author" content="Shengzhe Jin" /><meta name="citation_author_institution" content="School of Life Sciences, Zhengzhou University, Zhengzhou, China" /><meta name="citation_author" content="Yahong Wu" /><meta name="citation_author_institution" content="School of Life Sciences, Zhengzhou University, Zhengzhou, China" /><meta name="citation_author" content="Guanyu Chen" /><meta name="citation_author_institution" content="School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China" /><meta name="citation_author" content="Lu Qiu" /><meta name="citation_author_institution" content="School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China" /><meta name="citation_author" content="Wenjie Zhai" /><meta name="citation_author_institution" content="School of Life Sciences, Zhengzhou University, Zhengzhou, China" /><meta name="citation_author" content="Yanfeng Gao" /><meta name="citation_author_institution" content="School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China" /><meta name="citation_publication_date" content="2023" /><meta name="citation_issue" content="6" /><meta name="citation_volume" content="11" /><meta name="citation_doi" content="10.1136/jitc-2023-007068" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC10314633/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC10314633/" /><meta name="citation_pmid" content="37344099" /><meta name="DC.Title" content="Original research: Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="BMJ Publishing Group" /><meta name="DC.Contributor" content="Wenhui Shen" /><meta name="DC.Contributor" content="Peishang Shi" /><meta name="DC.Contributor" content="Qingyu Dong" /><meta name="DC.Contributor" content="Xiuman Zhou" /><meta name="DC.Contributor" content="Chunxia Chen" /><meta name="DC.Contributor" content="Xinghua Sui" /><meta name="DC.Contributor" content="Wentong Tian" /><meta name="DC.Contributor" content="Xueqin Zhu" /><meta name="DC.Contributor" content="Xiaoxi Wang" /><meta name="DC.Contributor" content="Shengzhe Jin" /><meta name="DC.Contributor" content="Yahong Wu" /><meta name="DC.Contributor" content="Guanyu Chen" /><meta name="DC.Contributor" content="Lu Qiu" /><meta name="DC.Contributor" content="Wenjie Zhai" /><meta name="DC.Contributor" content="Yanfeng Gao" /><meta name="DC.Date" content="2023" /><meta name="DC.Identifier" content="10.1136/jitc-2023-007068" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Original research: Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy" /><meta property="og:type" content="article" /><meta property="og:description" content="Aside from immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1), intervention of CD47/Sirp&#x003b1; mediated &#x02018;don&#x02019;t eat me&#x02019; signal between macrophage and tumor cell ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314633/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10314633/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/2348/">J Immunother Cancer</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/437840/">v.11(6); 2023</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC10314633
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC10314633/pdf/jitc-2023-007068.pdf" class="int-view">PDF (8.5M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/10314633/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/10314633/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="10314633" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10314633%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="xgPgzFJ5jLIHgr1cgpewlum0hvZJjSig1kEtaM3g9sLbIS6ktpp51Wm23mej3j5A">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10314633%2F&amp;text=Original%20research%3A%20Discovery%20of%20a%20novel%20dual-targeting%20D-peptide%20to%20block%20CD24%2FSiglec-10%20and%20PD-1%2FPD-L1%20interaction%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10314633%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314633/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC10314633/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/37344099/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC10314633/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/37344099/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC10314633/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/10314633/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/2348/">J Immunother Cancer</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/437840/">v.11(6); 2023</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC10314633
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-jimmthercanc.png" alt="Logo of jimmthercanc" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="https://jitc.bmj.com/" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">J Immunother Cancer.</span> 2023; 11(6): e007068. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2023 Jun 21. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.1136%2Fjitc-2023-007068" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1136/jitc-2023-007068</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC10314633</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37344099">37344099</a></div></div></div><h6 class="fm-ser-title no_margin">Original research</h6><h1 class="content-title">Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Shen%20W%5BAuthor%5D" id="author-99435409" class="affpopup" co-rid="_co_idm139632942109616" co-class="co-affbox">Wenhui Shen</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Shi%20P%5BAuthor%5D" id="author-102560845" class="affpopup" co-rid="_co_idm139632942108608" co-class="co-affbox">Peishang Shi</a>,<sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Dong%20Q%5BAuthor%5D" id="author-102560844" class="affpopup" co-rid="_co_idm139632891246864" co-class="co-affbox">Qingyu Dong</a>,<sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhou%20X%5BAuthor%5D" id="author-95477286" class="affpopup" co-rid="_co_idm139632891244640" co-class="co-affbox">Xiuman Zhou</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Chen%20C%5BAuthor%5D" id="author-102560846" class="affpopup" co-rid="_co_idm139632892408560" co-class="co-affbox">Chunxia Chen</a>,<sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sui%20X%5BAuthor%5D" id="author-81640684" class="affpopup" co-rid="_co_idm139632938683392" co-class="co-affbox">Xinghua Sui</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Tian%20W%5BAuthor%5D" id="author-106326900" class="affpopup" co-rid="_co_idm139632938681168" co-class="co-affbox">Wentong Tian</a>,<sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhu%20X%5BAuthor%5D" id="author-106326901" class="affpopup" co-rid="_co_idm139632903146432" co-class="co-affbox">Xueqin Zhu</a>,<sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20X%5BAuthor%5D" id="author-106326902" class="affpopup" co-rid="_co_idm139632903144208" co-class="co-affbox">Xiaoxi Wang</a>,<sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Jin%20S%5BAuthor%5D" id="author-102560837" class="affpopup" co-rid="_co_idm139632894964304" co-class="co-affbox">Shengzhe Jin</a>,<sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Wu%20Y%5BAuthor%5D" id="author-77385696" class="affpopup" co-rid="_co_idm139632905041312" co-class="co-affbox">Yahong Wu</a>,<sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Chen%20G%5BAuthor%5D" id="author-99435403" class="affpopup" co-rid="_co_idm139632905039088" co-class="co-affbox">Guanyu Chen</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Qiu%20L%5BAuthor%5D" id="author-102560850" class="affpopup" co-rid="_co_idm139632891057984" co-class="co-affbox">Lu Qiu</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhai%20W%5BAuthor%5D" id="author-77385682" class="affpopup" co-rid="_co_idm139632891055760" co-class="co-affbox">Wenjie Zhai</a>,<sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>2</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Gao%20Y%5BAuthor%5D" id="author-77363636" class="affpopup" co-rid="_co_idm139632894391264" co-class="co-affbox">Yanfeng Gao</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>1</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139632942109616"><h3 class="no_margin">Wenhui Shen</h3><p>
<sup>1</sup>
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Shen%20W%5BAuthor%5D">Wenhui Shen</a></div></div><div id="_co_idm139632942108608"><h3 class="no_margin">Peishang Shi</h3><p>
<sup>2</sup>
School of Life Sciences, Zhengzhou University, Zhengzhou, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Shi%20P%5BAuthor%5D">Peishang Shi</a></div></div><div id="_co_idm139632891246864"><h3 class="no_margin">Qingyu Dong</h3><p>
<sup>2</sup>
School of Life Sciences, Zhengzhou University, Zhengzhou, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Dong%20Q%5BAuthor%5D">Qingyu Dong</a></div></div><div id="_co_idm139632891244640"><h3 class="no_margin">Xiuman Zhou</h3><p>
<sup>1</sup>
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhou%20X%5BAuthor%5D">Xiuman Zhou</a></div></div><div id="_co_idm139632892408560"><h3 class="no_margin">Chunxia Chen</h3><p>
<sup>2</sup>
School of Life Sciences, Zhengzhou University, Zhengzhou, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Chen%20C%5BAuthor%5D">Chunxia Chen</a></div></div><div id="_co_idm139632938683392"><h3 class="no_margin">Xinghua Sui</h3><p>
<sup>1</sup>
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sui%20X%5BAuthor%5D">Xinghua Sui</a></div></div><div id="_co_idm139632938681168"><h3 class="no_margin">Wentong Tian</h3><p>
<sup>2</sup>
School of Life Sciences, Zhengzhou University, Zhengzhou, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Tian%20W%5BAuthor%5D">Wentong Tian</a></div></div><div id="_co_idm139632903146432"><h3 class="no_margin">Xueqin Zhu</h3><p>
<sup>2</sup>
School of Life Sciences, Zhengzhou University, Zhengzhou, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhu%20X%5BAuthor%5D">Xueqin Zhu</a></div></div><div id="_co_idm139632903144208"><h3 class="no_margin">Xiaoxi Wang</h3><p>
<sup>2</sup>
School of Life Sciences, Zhengzhou University, Zhengzhou, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20X%5BAuthor%5D">Xiaoxi Wang</a></div></div><div id="_co_idm139632894964304"><h3 class="no_margin">Shengzhe Jin</h3><p>
<sup>2</sup>
School of Life Sciences, Zhengzhou University, Zhengzhou, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Jin%20S%5BAuthor%5D">Shengzhe Jin</a></div></div><div id="_co_idm139632905041312"><h3 class="no_margin">Yahong Wu</h3><p>
<sup>2</sup>
School of Life Sciences, Zhengzhou University, Zhengzhou, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Wu%20Y%5BAuthor%5D">Yahong Wu</a></div></div><div id="_co_idm139632905039088"><h3 class="no_margin">Guanyu Chen</h3><p>
<sup>1</sup>
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Chen%20G%5BAuthor%5D">Guanyu Chen</a></div></div><div id="_co_idm139632891057984"><h3 class="no_margin">Lu Qiu</h3><p>
<sup>1</sup>
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Qiu%20L%5BAuthor%5D">Lu Qiu</a></div></div><div id="_co_idm139632891055760"><h3 class="no_margin">Wenjie Zhai</h3><p>
<sup>2</sup>
School of Life Sciences, Zhengzhou University, Zhengzhou, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhai%20W%5BAuthor%5D">Wenjie Zhai</a></div></div><div id="_co_idm139632894391264"><h3 class="no_margin">Yanfeng Gao</h3><p>
<sup>1</sup>
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Gao%20Y%5BAuthor%5D">Yanfeng Gao</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm139632895291312_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139632895291312_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139632895291312_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm139632895291312_ai" style="display:none"><div class="fm-affl" id="aff1">
<sup>1</sup>
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, China
</div><div class="fm-affl" id="aff2">
<sup>2</sup>
School of Life Sciences, Zhengzhou University, Zhengzhou, China
</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><div id="corresp-a.k.b.i.a"><sup>Correspondence to</sup>
 Professor Yanfeng Gao; <a href="mailto:dev@null" data-email="nc.ude.usys.liam@92fyoag" class="oemail">nc.ude.usys.liam@92fyoag</a>; Dr Wenjie Zhai; <a href="mailto:dev@null" data-email="nc.ude.uzz@iahzjw" class="oemail">nc.ude.uzz@iahzjw</a>
</div></div><div class="fm-article-notes hide half_rhythm" id="idm139632895291312_an" style="display:none"><div class="fm-pubdate half_rhythm">Accepted 2023 May 31.</div></div><div class="permissions half_rhythm hide" id="idm139632895291312_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</div><div class="license half_rhythm">This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <a href="https://creativecommons.org/licenses/by-nc/4.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">http://creativecommons.org/licenses/by-nc/4.0/</a>.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="2" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supplementary data.</strong></div><p>
<a href="/pmc/articles/PMC10314633/bin/jitc-2023-007068supp001.pdf">jitc-2023-007068supp001.pdf</a>
</p></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supplementary data.</strong></div><p>
<a href="/pmc/articles/PMC10314633/bin/jitc-2023-007068supp002.pdf">jitc-2023-007068supp002.pdf</a>
</p></div></dd></dl><dl data-length="43" class="box-data-avail whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-avl-stmnt" data-ga-action="click_feat_toggler" data-ga-label="Data Availability Statement" class="pmctoggle">Data Availability Statement</a></dt><dd id="data-avl-stmnt" style="display: none;"><p class="p p-first-last">Data are available upon reasonable request.</p></dd></dl></div><div id="abstract-a.k.b.r" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.k.b.rtitle">Abstract</h2><!--article-meta--><div><div id="sec-a.k.b.r.a" class="sec sec-first"><h3 id="sec-a.k.b.r.atitle">Background</h3><p class="p p-first-last">Aside from immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1), intervention of CD47/Sirp&#x003b1; mediated &#x02018;don&#x02019;t eat me&#x02019; signal between macrophage and tumor cell is considered as a promising therapeutic approach for cancer immunotherapy. Compared with CD47, the novel immune checkpoint CD24/Siglec-10 can also deliver &#x02018;don&#x02019;t eat me&#x02019; signal and CD24 shows much lower expression level in normal tissue which might avoid unwanted side effects.</p></div><div id="sec-a.k.b.r.b" class="sec"><h3 id="sec-a.k.b.r.btitle">Methods</h3><p class="p p-first-last">Cell-based phage display biopanning and D-amino acid modification strategy were used to identify the CD24/Siglec-10 blocking peptide. Cell-based blocking assay and microscale thermophoresis assay were used to validate the blocking and binding activities of the peptide. Phagocytosis and co-culture assays were used to explore the in vitro function of the peptide. Flow cytometry was performed to assess the immune microenvironment after the peptide treatment in vivo.</p></div><div id="sec-a.k.b.r.c" class="sec"><h3 id="sec-a.k.b.r.ctitle">Results</h3><p class="p p-first-last">A CD24/Siglec-10 blocking peptide (CSBP) with hydrolysis-resistant property was identified. Surprisingly, we found that CSBP could not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CSBP could induce the phagocytosis of tumor cell by both the macrophages and monocytic myeloid-derived suppressor cells (M-MDSCs), which can further activate CD8<sup>+</sup> T cells. Besides, combination of radiotherapy and CSBP synergistically reduced tumor growth and altered the tumor microenvironment in both anti-PD-1-responsive MC38 and anti-PD-1-resistant 4T1 tumor models.</p></div><div id="sec-a.k.b.r.d" class="sec sec-last"><h3 id="sec-a.k.b.r.dtitle">Conclusions</h3><p class="p p-first-last">In summary, this is the first CD24/Siglec-10 blocking peptide which blocked PD-1/PD-L1 interaction as well, functioned <em>via</em> enhancing the phagocytosis of tumor cells by macrophages and M-MDSCs, and elevating the activity of CD8<sup>+</sup> T cells for cancer immunotherapy.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">macrophages, radiotherapy, tumor microenvironment, immunotherapy</span></div></div><div id="body-a.l" class="tsec sec"><h2 class="headless nomenu"></h2><div class="boxed-text-box whole_rhythm hide-overflow" id="BX1"><div class="sec"><h3 id="sec-a.l.a.atitle">WHAT IS ALREADY KNOWN ON THIS TOPIC</h3><ul class="unordered" style="list-style-type:disc"><li><div>Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) have been approved for the treatment of a variety of cancer types. However, only a small subset of patients with cancer can benefit from ICIs.</div></li><li><div>CD24/Siglec-10 interaction can deliver &#x02018;don&#x02019;t eat me&#x02019; anti-phagocytic signals between macrophages and tumor cells.</div></li></ul></div><div class="sec"><h3 id="sec-a.l.a.btitle">WHAT THIS STUDY ADDS</h3><ul class="unordered" style="list-style-type:disc"><li><div>CD24/Siglec-10 blocking peptide (CSBP) is the first reported blocking peptide that can enhance macrophage-mediated phagocytosis of tumor cells and activate CD8<sup>+</sup> T cells by simultaneously blocking the interaction of CD24/Siglec-10 and PD-1/PD-L1.</div></li><li><div>We discovered that monocytic myeloid-derived suppressor cells could also mediate phagocytosis effects.</div></li><li><div>CSBP synergistically inhibits tumor growth combined with radiotherapy in both anti-PD-1-responsive MC38 tumor model and anti-PD-1-resistant 4T1 tumor model.</div></li></ul></div><div class="sec"><h3 id="sec-a.l.a.ctitle">HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY</h3><ul class="unordered" style="list-style-type:disc"><li><div>CSBP can improve cancer immunotherapy with high therapeutic efficacy by harnessing both innate and adaptive immune responses.</div></li></ul></div></div></div><div id="s1" class="tsec sec"><h2 class="head no_bottom_margin" id="s1title">Introduction</h2><p class="p p-first">In the past few years, there have been significant clinical advances in cancer immunotherapy. The immune checkpoint blockade (ICB) strategies have demonstrated unprecedented extension of patient survival, and antibodies targeting programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) have been approved to treat various types of cancer, including melanoma and Hodgkin&#x02019; lymphoma.<a href="#R1" rid="R1" class=" bibr popnode">1</a> However, only a small subset of patients with cancer can benefit from the immune checkpoint inhibitors (ICIs). The insufficient clinical responses of PD-1/PD-L1 blockade have been reported to be attributed to several reasons, such as low-expression of PD-L1, low immune cell infiltration, low tumor mutation burden and so on.<a href="#R2" rid="R2" class=" bibr popnode">2</a> Therefore, it is urgent to discover novel drug targets for developing therapeutic agents and combination strategies to enhance the response rate of cancer immunotherapy.</p><p>Different from the blockade of PD-1/PD-L1 to initiate antitumor immune response through CD8<sup>+</sup> T cells, interference of the &#x02018;don&#x02019;t eat me&#x02019; pathway mediated by macrophages has many advantages.<a href="#R3" rid="R3" class=" bibr popnode">3</a> First, the distribution of macrophage is more common in most solid tumors than CD8<sup>+</sup> T cell. Second, the antigen from the phagocytosed tumor cell can be subsequently processed and presented to T cell by macrophages, which can also function as antigen-presenting cells.<a href="#R4" rid="R4" class=" bibr popnode">4</a> Therefore, several involving pathways have been reported and considered as therapeutic targets, especially CD47/Sirp&#x003b1;. Antibodies and fusion proteins targeting CD47 were developed and studied clinically.<a href="#R5" rid="R5" class=" bibr popnode">5</a> Unfortunately, because of the wide expression of CD47 in normal tissues as well, side effects and low therapeutic efficacy often arise mainly caused by non-tumor-targeting.<a href="#R6" rid="R6" class=" bibr popnode">6</a> Due to the relatively weak receptor occupation and promising tumor penetration properties of small peptides compared with antibodies, thus we have developed a small peptide to block CD47/Sirp&#x003b1; previously, which could elicit antitumor effects alone or combined with radiotherapy (RT) without significant toxicity.<a href="#R7" rid="R7" class=" bibr popnode">7</a> Therefore, it is a promising strategy to develop small peptides as therapeutic agents targeting immune checkpoints.</p><p>Recently, another &#x02018;don&#x02019;t eat me&#x02019; pathway, CD24/Siglec-10, has been revealed.<a href="#R8" rid="R8" class=" bibr popnode">8</a> CD24 is a mucin-like glycosylphosphatidylinositol-anchored glycoprotein, which is expressed in murine hematopoietic cell subpopulations, including B lymphocytes,<a href="#R9" rid="R9" class=" bibr popnode">9</a> the majority of thymocytes,<a href="#R10" rid="R10" class=" bibr popnode">10</a> erythrocytes and neutrophils.<a href="#R11" rid="R11" class=" bibr popnode">11 12</a> CD24 is responsible for proliferation of T lymphocytes as a co-stimulatory molecule, as it is crucial for the homeostatic proliferation of T cells in the lymphopenic environment.<a href="#R13" rid="R13" class=" bibr popnode">13</a> More importantly, compared with CD47, CD24 is absent on human erythrocytes or thymocytes but highly expressed in various cancer cells and cancer stem cells.<a href="#R8" rid="R8" class=" bibr popnode">8</a> CD24 has been identified as a prognostic marker in patients with ovarian cancer,<a href="#R14" rid="R14" class=" bibr popnode">14</a> lung cancer,<a href="#R15" rid="R15" class=" bibr popnode">15</a> and it is also involved in the migration and metastasis of glioblastoma cells and osteosarcoma cells.<a href="#R16" rid="R16" class=" bibr popnode">16 17</a> Therefore, CD24 has recently attracted much attention as a potential drug target against cancer cells or cancer stem cells.</p><p>CD24 interacted with Siglec-10, relaying anti-phagocytic signals to cause tumor cells to evade immune killing. Accordingly, anti-CD24 could induce macrophage-mediated phagocytosis of ovarian cancer and breast cancer cells and reduce tumor burden in MCF-7 tumor model.<a href="#R8" rid="R8" class=" bibr popnode">8</a> The expression of CD24 is higher than PD-L1 in several cancers, including which resistant to anti-PD-1 therapy.<a href="#R8" rid="R8" class=" bibr popnode">8</a> As CD24 is overexpressed in tumor tissues whereas rarely detected in normal tissues, it is necessary to further determine the potential and develop therapeutic agents to block CD24/Siglec-10 for cancer immunotherapy.</p><p>The anti-CD24 monoclonal antibody (mAb) SWA11 effectively inhibited tumor cell proliferation and angiogenesis with retarding ovarian carcinoma xenografts growth.<a href="#R18" rid="R18" class=" bibr popnode">18</a> In CD24-positive triple negative breast cancer (TNBC), CD24 mAb (ALB9) treatment significantly reduced lung tumor growth and greatly prolonged the survival of mice.<a href="#R19" rid="R19" class=" bibr popnode">19</a> Compared with proteins and antibodies, small peptides are less immunogenic and have better tumor permeability. Peptides are generally low-cost and easy to synthesize. On the other hand, compared with small molecules, peptides are usually characterized by lower toxicity, higher efficacy and specificity. <a href="#R20" rid="R20" class=" bibr popnode">20</a> In the previous studies, we have identified small peptides as ICIs targeting PD-1/PD-L1, lymphocyte activation gene 3 (LAG-3)/major histocompatibility complex (MHC)-II, T cell immunoreceptor with Ig and ITIM domains (TIGIT)/poliovirus receptor (PVR) and CD47/Sirp&#x003b1;, respectively.<a href="#R7" rid="R7" class=" bibr popnode">7 21&#x02013;23</a> However, the development of peptide drugs targeting the &#x02018;don&#x02019;t eat me&#x02019; signal CD24/Siglec-10 has not been reported yet.</p><p class="p p-last">Here, the CD24 and CD47 expression was analyzed and compared, and the phage display peptide library biopanning technology was used to screen CD24 binding peptides. Retro-inversion and glutamic acid substitution strategies were performed to improve the hydrolysis-resist ability and solubility, respectively. By using a cell-based blocking assay, an 8-mer CD24/Siglec-10 blocking peptide (CSBP) composed of D-amino acids was identified. Surprisingly, CSBP could also block the interaction of PD-1/PD-L1, which resulted in promoting the phagocytosis of macrophages and activating CD8<sup>+</sup> T cells. We also investigated whether CSBP could enhance the phagocytosis of monocytic myeloid-derived suppressor cell (M-MDSC). Finally, the antitumor response of CSBP alone or combined with RT was studied. Thus, this study proposed new insights and strategies to harness both myeloid cells and T cells for cancer immunotherapy, by using small peptides as dual-targeting ICIs combined with RT.</p></div><div id="s2" class="tsec sec"><h2 class="head no_bottom_margin" id="s2title">Materials and methods</h2><div id="s2-1" class="sec sec-first"><h3 id="s2-1title">Cell lines</h3><p class="p p-first-last">MDA-MB-231, HT29, 4T1 and CT26 cells were grown in RPMI-1640 medium, and MDA-MB-453, MDA-MB-468 and MC38 cells were cultured in DMEM. The medium contained 10% fetal bovine serum (Gibco, Grand Island, New York, USA), 1% penicillin/streptomycin solution.</p></div><div id="s2-2" class="sec"><h3 id="s2-2title">Mouse tumor models</h3><p class="p p-first">For MC38 model, 1&#x000d7;10<sup>6</sup> MC38 cells were subcutaneously injected into the right flank of 35 female SPF-level C57BL/6 mice (6-week-old) randomly divided into seven groups to develop the subcutaneous tumor bearing model. The sample size was determined according to the previous research results of our group and others. For CSBP treatment, 2&#x02009;mg/kg of CSBP was daily injected intraperitoneally (<em>i.p</em>.) into the mice. For antibodies, 400&#x02009;&#x000b5;g of anti-mouse CD47 antibody (miap301, Bio X Cell, USA), 250&#x02009;&#x000b5;g of anti-PD-L1 (10F.9G2, Bio X Cell, USA), 200&#x02009;&#x000b5;g of anti-CD24 (M1/69, Bio X Cell, USA), or 250&#x02009;&#x000b5;g of anti-PD-L1 plus 200&#x02009;&#x000b5;g of anti-CD24, were injected <em>i.p</em>. into the mice every 3&#x02009;days. Phosphate buffered saline containing 5% DMSO and rat IgG were used as the negative controls, respectively. Tumor volumes were measured every other day by length (a), width (b) and height (c), and calculated as tumor volume=abc/2. Treatment was continued for 2 weeks, then the mice were euthanized, tumors, spleens and draining lymph nodes were dissected. For macrophages depletion, 150&#x02009;&#x000b5;L of clodronate liposomes or control liposomes (FormuMax Scientific, USA) were injected <em>i.p</em>. into C57BL/6 mice. The efficiency of macrophages depletion was tested by analyzing the CD45<sup>+</sup> CD11b<sup>+</sup> F4/80<sup>+</sup> cells. For M-MDSCs depletion, 100&#x02009;&#x000b5;g of anti-mouse Gr-1 (RB6-8C5, Bio X Cell, USA) was delivered by <em>i.p</em>. injection every 3&#x02009;days with rat IgG as the negative controls. The efficiency of M-MDSCs depletion was tested by analysis of the CD45<sup>+</sup> CD11b<sup>+</sup> Ly6G<sup>&#x02212;</sup> Ly6C<sup>+</sup> cells. In the MC38 RT model, tumor-bearing mice were treated with local 20&#x02009;Gy RT, and CSBP (2&#x02009;mg/kg) was administered <em>i.p</em>. to mice daily.</p><p class="p p-last">For the 4T1 model, 5&#x000d7;10<sup>4</sup> 4T1 cells were inoculated orthotopically in the BALB/c mice mammary fat pad. In the 4T1 RT model, tumor-bearing mice were treated 12&#x02009;Gy RT twice and treated with CSBP (2&#x02009;mg/kg) daily.</p></div><div id="s2-3" class="sec sec-last"><h3 id="s2-3title">Statistical analysis</h3><p class="p p-first-last">Differences between groups were analyzed by unpaired Student&#x02019;s t-test or two-way analysis of variance. All data are presented as means&#x000b1;SEM. Statistical analyses were carried out using Prism V.8.0 statistical software (GraphPad Software). Flow cytometry data were analyzed by FlowJo V.10. Significant differences between the groups are indicated by *p&#x0003c;0.05, **p&#x0003c;0.01, ***p&#x0003c;0.001.</p></div></div><div id="s3" class="tsec sec"><h2 class="head no_bottom_margin" id="s3title">Results</h2><div id="s3-1" class="sec sec-first"><h3 id="s3-1title">CD24 is overexpressed in tumor tissues and associated with poor prognosis</h3><p class="p p-first">The CD24 expression was assessed in tumor and normal tissues <em>via</em> analyzing the UALCAN data portal, which revealed that CD24 was overexpressed in several cancer types, such as kidney renal papillary cell carcinoma, esophageal carcinoma, and breast invasive carcinoma (BRCA) (<a href="/pmc/articles/PMC10314633/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>figure 1A</span></a>). The high expression of CD24 was associated with poor prognosis in BRCA (p=0.00021), mesothelioma (p=0.0034), cervical squamous cell carcinoma and endocervical adenocarcinoma (p=0.045) using gene expression profiling interactive analysis (GEPIA) (<a href="/pmc/articles/PMC10314633/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>figure 1B</span></a>). Interestingly, the expression of CD24 differed in BRCA subtypes, and it was significantly higher in TNBC basal-like 1 than that in normal breast, luminal or HER2<sup>+</sup> BRCA (<a href="/pmc/articles/PMC10314633/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>figure 1C</span></a>). The expression level of CD24 was much higher than that of PD-L1 in most BRCA subtypes (<a href="/pmc/articles/PMC10314633/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>figure 1C</span></a>). In addition, single-cell RNA-sequencing data demonstrated that CD24 was expressed higher than PD-L1 in both T-cell expansion and T-cell non-expansion groups after anti-PD-1 treatment (<a href="/pmc/articles/PMC10314633/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>figure 1D</span></a>).<a href="#R24" rid="R24" class=" bibr popnode">24</a> The CD24 and PD-L1 expression on various tumor cell lines were displayed (<a href="/pmc/articles/PMC10314633/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>figure 1E</span></a>). CD24 and CD47 expression were highly expressed in multiple tumor types by analyzing GEPIA (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S1A</a>). Meanwhile, the BioGPS database results suggested that the expression of CD47 was significantly higher than that of CD24 expression in most of the normal tissues, such as skin, liver, pituitary, lung and heart (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S1B</a>). These results illustrated the advantages of CD24 as a potential drug target for immunotherapy.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC10314633/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139632899133808"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10314633_jitc-2023-007068f01.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is jitc-2023-007068f01.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10314633/bin/jitc-2023-007068f01.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139632899133808"><a target="object" rel="noopener" href="/pmc/articles/PMC10314633/figure/F1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC10314633/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><p>CD24 is significantly overexpressed in tumors. (A) Expression of CD24 across multiple human cancers (red) compared with corresponding normal tissues (blue) obtained from the UALCAN database. (B) The overall survival curve of human cancers with high and low CD24 expression analyzed by the GEPIA. (C) Expression of PD-L1 and CD24 in BRCA major subclasses <em>via</em> UALCAN database. (D) Expression analysis of PD-L1 and CD24 in human TNBC cells from patients (n=5) where T expansion or no-expansion to anti-PD-1 immunotherapy across single cell sequencing illustrated. (E) Expression of CD24 and PD-L1 on human or mouse tumor cell lines was detected by flow cytometry, gray shading indicates matched isotype controls. Data are presented as means&#x000b1;SEM, and statistical significance was determined by unpaired Student&#x02019;s t-test. <em>*</em>p&#x0003c;0.05, <em>**</em>p&#x0003c;0.01, <em>***</em>p&#x0003c;0.001. BLCA, bladder Urothelial Carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; GEPIA, gene expression profiling interactive analysis; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; PCPG, pheochromocytoma and paraganglioma; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; PRAD, prostate adenocarcinoma; STAD, stomach adenocarcinoma; TNBC, triple negative breast cancer.</p></div></div></div><div class="sec suppmat" id="SP1"><h4>Supplementary data</h4><p>
<a href="/pmc/articles/PMC10314633/bin/jitc-2023-007068supp001.pdf" id="SS1">jitc-2023-007068supp001.pdf</a>
</p></div></div><div id="s3-2" class="sec"><h3 id="s3-2title">Screening of candidate peptides binding CD24 via a cell-based phage display biopanning</h3><p class="p p-first-last">To obtain CD24-binding peptides, a random 7-mer peptide library was used for the cell-based phage display biopanning. High-affinity phages were productively enriched after four rounds of screening. We isolated and sequenced the DNA of the phage clones, then the sequences of corresponding peptides were aligned <em>via</em> Clustal Omega. Finally, peptides with different common sequences were selected, and their sequences were displayed in <a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental table S1</a>. The blocking activity of candidate peptides for CD24/Siglec-10 interaction was verified by the blocking assay. As shown in <a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental table S1</a>, the blocking rates of peptide-9, peptide-6 and peptide-5 were 55.70%, 39.03% and 18.43%, respectively. Therefore, peptide-9 with the highest blocking rate was selected as the candidate peptide. Alanine scanning of peptide-9 was performed to help further rationalized modifications.<a href="#R25" rid="R25" class=" bibr popnode">25</a> The results confirmed that each amino acid was essential for blocking CD24/Siglec-10 interaction, with L3, F4 and V5 were the key residues to interact with CD24 (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental table S2</a>). Peptide-9 was named blocking peptide (BP) for further investigation.</p></div><div id="s3-3" class="sec"><h3 id="s3-3title">CSBP binds CD24 and PD-L1, targeting CD24/Siglec-10 and PD-1/PD-L1 pathways</h3><p class="p p-first">L-amino acids were sensitive to proteases and could be degraded easily.<a href="#R26" rid="R26" class=" bibr popnode">26</a> To improve the hydrolysis stability of BP, we attempted to transform some L-amino acids into D-configuration amino acids.<a href="#R27" rid="R27" class=" bibr popnode">27</a> According to the alanine scanning results, L-amino acids were substituted with D-amino acids except for L3, F4 and V5, and the retro-inverso peptide harboring the reverse sequence of BP was also designed. As shown in <a href="/pmc/articles/PMC10314633/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>figure 2A</span></a>, the retro-inverso peptide (<sup>D</sup>BP-1) was able to block the interaction of CD24/Siglec-10, but the decreased blocking ability was observed in BP-2 and BP-3. To increase the solubility of <sup>D</sup>BP-1, C-terminal and N-terminal residues were modified by the hydrophilic glutamic acid.<a href="#R28" rid="R28" class=" bibr popnode">28</a> We found that C1e (CSBP) exhibited greater blocking activity than <sup>D</sup>BP-1 (<a href="/pmc/articles/PMC10314633/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>figure 2A</span></a>). CSBP exhibited dose-dependent effect to block human CD24/Siglec-10 interaction with a good affinity to human CD24 (K<sub>D</sub>=9.22&#x000b1;6.47&#x02009;&#x000b5;M) (<a href="/pmc/articles/PMC10314633/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>figure 2B, C</span></a>). Interestingly, we found that CSBP also blocked the human PD-1/PD-L1 interaction (IC<sub>50</sub>=30.25&#x000b1;0.24&#x02009;&#x000b5;M) (<a href="/pmc/articles/PMC10314633/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>figure 2D</span></a>). Additionally, CSBP illustrated good affinity to human PD-L1 (K<sub>D</sub>=7.53&#x000b1;4.17&#x02009;&#x000b5;M) (<a href="/pmc/articles/PMC10314633/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>figure 2E</span></a>). Due to the lack of commercial availability of mouse Siglec-10 protein, we attempted to test whether human Siglec-10 could bind to 4T1 cells overexpressing murine CD24. The results demonstrated that human Siglec-10 could bind to 4T1 cells overexpressing murine CD24. The high similarity between human Siglec-10 and mouse Siglec-10 with an overall homology of about 60% can explain this phenomenon. Peptide CSBP demonstrated relative high blocking effect on mCD24/hSiglec-10 interaction (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S2A</a>), and exhibited an affinity to mCD24 (K<sub>D</sub>=0.22&#x000b1;0.18&#x02009;&#x000b5;M) (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S2B</a>). The blockade of CSBP to mouse PD-1/PD-L1 interaction was determined (IC<sub>50</sub>=55.64&#x000b1;0.14&#x02009;&#x000b5;M), and the affinity with mouse PD-L1 was determined (K<sub>D</sub>=22.9&#x000b1;14.7&#x02009;&#x000b5;M) (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S2C, D</a>). To verify the stability of CSBP, the kinetics of degradation were monitored by reverse phase-high performance liquid chromatography (RP-HPLC). CSBP exhibited resistance to protease degradation in 10% human serum or mouse serum (<a href="/pmc/articles/PMC10314633/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>figure 2F, G</span></a>; <a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S2E, F</a>). These results suggested that peptide CSBP could block CD24/Siglec-10 and PD-1/PD-L1 interactions and was hydrolysis-resistant in the serum.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC10314633/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139632901946720"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10314633_jitc-2023-007068f02.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is jitc-2023-007068f02.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10314633/bin/jitc-2023-007068f02.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139632901946720"><a target="object" rel="noopener" href="/pmc/articles/PMC10314633/figure/F2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC10314633/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><p>Characterization of bispecific peptide targeting CD24/PD-L1. (A) Blocking activities of optimized peptides. (B) In vitro blocking activity of CSBP on the human CD24/hSiglec-10 interaction as measured by flow cytometry. (C) In vitro binding affinity of CSBP on human CD24 as measured by MST. (D) In vitro blocking activity of CSBP on the human PD-1/PD-L1 interaction as measured by flow cytometry. (E) Binding affinity of CSBP on human PD-L1 as measured by MST. (F) Representative HPLC analysis of CSBP hydrolysis in 10% human serum. (G) The residual peptide time-dependent curve. Data are presented as means&#x000b1;SEM. BP, blocking peptide; CSBP, CD24/Siglec-10 blocking peptide; HPLC, high performance liquid chromatography; MST, microscale thermophoresis; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1.</p></div></div></div><p class="p p-last">To explore whether CSBP could target the CD24/Siglec-10 and PD-1/PD-L1 interactions, we measured the blocking activity of CSBP on other immune checkpoints, including CD47/Sirp&#x003b1;, TIGIT/PVR, LAG-3/FGL1 and LAG-3/MHC-&#x02161;. The results showed that CSBP did not exert blocking activity in these targets (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S3A</a>). In addition, among other peptides blocking CD24/Siglec-10 interaction, N2e could also simultaneously block the PD-1/PD-L1 interaction (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S3B</a>). While the previously discovered PD-1/PD-L1 targeting peptide OPBP-1 and the CD47/Sirp&#x003b1; targeting peptide pep-20 were unable to block CD24/Siglec-10 (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S3C</a>).<a href="#R7" rid="R7" class=" bibr popnode">7 29</a> In order to study the mechanism of CSBP targeting CD24/Siglec-10 and PD-1/PD-L1, the ESPript was used to generate sequence alignment. The results indicated that the sequences of the Siglec-10 IgV domain were partly consistent with PD-1, among which Leu128, Ala132, Ile134 and Glu136 were the key residues to interact with PD-L1 (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S3D</a>). We next predicted Siglec-10 and CSBP structure by PEP-FOLD3. Three-dimensional structural prediction and molecular docking analysis (MOE) were used to compare structural similarity between PD-1 (PDB: 4ZQK) and Siglec-10 protein (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S3E</a>). The key residues and binding regions of CSBP and PD-L1 protein were simulated by the MOE. CSBP might interact with PD-L1 (PDB: 5C3T) through Asp2-Arg113, Val3-Glu58, Glu8-Gln66, among which Arg113, Glu58 and Gln66 were the key residues to interact with PD-1 (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S3F</a>). The interaction residues of CSBP and CD24 were not analyzed due to the lack of crystal structure of CD24 and CD24/Siglec-10 interface. These results suggested that CSBP may target CD24/Siglec-10 and PD-1/PD-L1 because of the similarity of the amino acid sequence and protein structure between PD-1 and Siglec-10 protein.</p></div><div id="s3-4" class="sec"><h3 id="s3-4title">CSBP enhances macrophage-mediated and M-MDSC-mediated phagocytosis of tumor cells and potentiates the function of CD8<sup>+</sup> T cells in vitro</h3><p class="p p-first">Human Siglec-10 has been reported to be expressed on tumor-associated macrophages (TAMs). We observed the expression of mouse Siglec-G (homologue of human Siglec-10 in murine) in TAMs, the M-MDSC and granulocytic myeloid-derived suppressor cells (G-MDSC) (<a href="/pmc/articles/PMC10314633/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>figure 3A</span></a>). Then, we investigated whether CSBP could enhance the phagocytosis of CD24<sup>+</sup> tumor cells. CSBP showed no cytotoxic effects on 4T1 and MC38 cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S4A</a>). Incubation of 4T1 and MC38 cells with CSBP or anti-CD47 antibody (positive control) treatment resulted in significant phagocytosis by bone marrow-derived macrophages (BMDM) (<a href="/pmc/articles/PMC10314633/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>figure 3B</span></a>; <a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S4B</a>). The splenocytes of 4T1 tumor-bearing mice were co-cultured with 4T1 labeled with carboxyfluorescein succinimidyl ester (CFSE) for 2&#x02009;hours to detect macrophage and M-MDSC-mediated phagocytosis. Amazingly, we found the phagocytosis of 4T1 cells exhibited a significant increase not only to macrophage but also to M-MDSC, after treatment of CSBP or anti-CD47 antibody (<a href="/pmc/articles/PMC10314633/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>figure 3C, D</span></a>). To explore whether CD8<sup>+</sup> T cells can be primed after CSBP-mediated phagocytosis by macrophages, we examined the percentage of proliferating CD8<sup>+</sup> T cells via CFSE assay. BMDM were co-cultured with 4T1 cells in the presence of CSBP. The percentage of proliferating CD8<sup>+</sup> T cells and the ratio of interferon (IFN)-&#x003b3;-expressing T cells were significantly increased, which indicated that it could activate CD8<sup>+</sup> T-cell immune activity following macrophage-mediated phagocytosis by CSBP (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure 5A, B</a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC10314633/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139632899790000"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10314633_jitc-2023-007068f03.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is jitc-2023-007068f03.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10314633/bin/jitc-2023-007068f03.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139632899790000"><a target="object" rel="noopener" href="/pmc/articles/PMC10314633/figure/F3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC10314633/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3</a></div><!--caption a7--><div class="caption"><p>4T1 cancer cells phagocytosis by macrophage/M-MDSC and T-cell activation after CSBP treatment. (A) Representative flow cytometry histogram of the expression of mSiglec-G (black lines) versus isotype control (gray shaded curves) by macrophage, M-MDSC or G-MDSC. (B) Phagocytosis assays were performed with CD24<sup>+</sup> 4T1 cells by BMDMs in the presence of CSBP or anti-CD47 mAb. (C, D) Flow cytometry analysis of phagocytosis of 4T1 cells by macrophages and M-MDSCs from 4T1 tumor-bearing mice spleen, in the presence of CSBP or anti-CD47 mAb. (E) Evaluation of the effects of CSBP on IL-2-expressing Jurkat T cells. Intracellular staining of IL-2 was detected by flow cytometry. (F, G) PBMCs from healthy donors were isolated and stained with 0.2&#x02009;&#x000b5;M CFSE. Then, PBMCs were activated with 100&#x02009;U/mL IL-2, 1&#x02009;&#x000b5;g/mL anti-CD3, and 1&#x02009;&#x000b5;g/mL anti-CD28 stimulatory antibodies, and cultured with CHO-K1-Vec or CHO-K1-hPD-L1 cells with or without CSBP. After 3&#x02009;days, the proliferation of CD8<sup>+</sup> T cells and proportion of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells were analyzed by flow cytometry. Data are representative of at least three independent experiments. Data are presented as means&#x000b1;SEM, and statistical significance was determined by two-way analysis of variance with multiple comparisons. *p&#x0003c;0.05, **p&#x0003c;0.01, ***p&#x0003c;0.001. BMDMs, bone marrow-derived macrophages; CFSE, carboxyfluorescein succinimidyl ester; CSBP, CD24/Siglec-10 blocking peptide; G-MDSC, granulocytic myeloid-derived suppressor cell; IFN, interferon; IL, interleukin; mAb, monoclonal antibody; M-MDSC, monocytic myeloid-derived suppressor cell; PBMCs, peripheral blood mononuclear cells.</p></div></div></div><p class="p p-last">To prove the effect of CSBP blocking the PD-1/PD-L1 pathway, Jurkat cells were used as a model T-cell line. When Jurkat cells were co-cultured with PD-L1 overexpressed CHO-K1-hPD-L1 cells, the proportion of interleukin (IL)-2<sup>+</sup> CD45<sup>+</sup> T cells decreased from 9.61% to 4.08%. The proportion of IL-2<sup>+</sup> CD45<sup>+</sup> T cells restored to 8.4% after CSBP treatment (<a href="/pmc/articles/PMC10314633/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>figure 3E</span></a>). Relative to co-cultured with CHO-K1-Vec cells which did not express PD-L1, the proportion of IL-2<sup>+</sup> CD45<sup>+</sup> T cells was unaffected in the presence or absence of CSBP. To further determine this promotion effect induced by CSBP depended on the blocking of PD-1/PD-L1, human peripheral blood mononuclear cells (PBMCs) were co-cultured with PD-L1 overexpressed CHO-K1-hPD-L1 for 3&#x02009;days. The results indicated that PD-1/PD-L1 interaction directly inhibited the proliferation of CD8<sup>+</sup> T cells and reduced the proportion of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells, which were restored by CSBP treatment (<a href="/pmc/articles/PMC10314633/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>figure 3F, G</span></a>). When PBMCs were co-cultured with CHO-K1-Vec cells which did not express PD-L1, the proliferation of CD8<sup>+</sup> T cells and proportion of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells were not affected with or without CSBP, which were consistent with the results from Jurkat cells co-culture assay. Based on the results, it can be concluded that CSBP abrogated the PD-1/PD-L1 axis-mediated dysfunction of T cells, further suggesting that CSBP could regulate T-cell function by blocking PD-1/PD-L1 interaction. In conclusion, CSBP could activate CD8<sup>+</sup> T cells both indirectly through macrophage-mediated phagocytosis and directly by blocking PD-1/PD-L1 interaction.</p></div><div id="s3-5" class="sec"><h3 id="s3-5title">CSBP inhibits tumor growth in MC38 model</h3><p class="p p-first">MC38 tumor model was performed to test the responses of cytotoxic T cells against cancer cells, including PD-1/PD-L1 blockade. We first explored the antitumor response of CSBP in this model. Besides, we evaluated the antitumor response of CSBP with other groups, including anti-PD-L1, anti-CD24, and anti-PD-L1 plus anti-CD24. Although anti-PD-L1 and anti-CD24 significantly inhibited tumor growth, the tumor volume was bigger than the treatment with CSBP. Moreover, the antitumor response of CSBP was similar to that of anti-PD-L1 plus anti-CD24 treatment (<a href="/pmc/articles/PMC10314633/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>figure 4A, B</span></a>). Compared with anti-CD24 or anti-PD-L1 monotherapy, the CSBP treatment group significantly enhanced the percentage of tumor-infiltrating T cells (<a href="/pmc/articles/PMC10314633/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>figure 4C</span></a>). Also, CSBP simultaneously enhanced the cytotoxic activity of T cells. The percentage of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells was increased with CSBP treatment, compared with anti-PD-L1 or anti-CD24 monotherapy (<a href="/pmc/articles/PMC10314633/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>figure 4D</span></a>). In addition to T cells, CSBP increased the ratio of M1/M2 (<a href="/pmc/articles/PMC10314633/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>figure 4E</span></a>). Furthermore, the CSBP treatment group increased the frequency of M-MDSCs. The frequency of M-MDSCs in the CSBP-treated group showed higher than that in other groups (<a href="/pmc/articles/PMC10314633/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>figure 4F</span></a>). In addition, the CSBP treatment group showed an increased percentage of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells in draining lymph nodes and spleens, compared with treatment of anti-PD-L1 or anti-CD24 (<a href="/pmc/articles/PMC10314633/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>figure 4G, H</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F4" co-legend-rid="lgnd_F4"><a href="/pmc/articles/PMC10314633/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139632873598160"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10314633_jitc-2023-007068f04.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is jitc-2023-007068f04.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10314633/bin/jitc-2023-007068f04.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139632873598160"><a target="object" rel="noopener" href="/pmc/articles/PMC10314633/figure/F4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F4"><div><a class="figpopup" href="/pmc/articles/PMC10314633/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4">Figure 4</a></div><!--caption a7--><div class="caption"><p>CSBP inhibits tumor growth in MC38 tumor model. (A) Schematic of the dosing schedule time points for treatment groups. (B) The tumor growth curves of MC38-bearing mice receiving the treatment of CSBP or antibodies. Data are presented as the means&#x000b1;SEM (n=5 per group). (C) The percentage of tumor-infiltrating CD8<sup>+</sup> T cells in total CD45<sup>+</sup> cells was determined by flow cytometry (n=5). (D) The frequency of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells was detected by flow cytometry (n=5). (E) Flow cytometric analysis of M1/M2 ratio in the TME after CSBP or antibodies treatment (n=5). M1, CD45<sup>+</sup> CD11b<sup>+</sup> F4/80<sup>+</sup> CD11c<sup>+</sup> CD206<sup>&#x02212;</sup>; M2, CD45<sup>+</sup> CD11b<sup>+</sup> F4/80<sup>+</sup> CD206<sup>+</sup> CD11c<sup>&#x02212;</sup>. (F) Percentages of myeloid-derived suppressor cell within the TME in each group (n=5). G-MDSC, CD45<sup>+</sup> CD11b<sup>+</sup> Ly6G<sup>+</sup> Ly6C<sup>&#x02212;</sup>; M-MDSC, CD45<sup>+</sup> CD11b<sup>+</sup> Ly6G<sup>&#x02212;</sup> Ly6C<sup>+</sup>. (G, H) Cells from mice draining lymph nodes (G) or spleens (H) were obtained and stimulated with 20&#x02009;ng/mL of PMA and 1&#x02009;&#x000b5;M ionomycin containing protein transport inhibitor cocktail for 4&#x02009;hours. Frequencies of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells were detected by flow cytometry (n=5). Data are presented as means&#x000b1;SEM, and statistical significance was determined by two-way analysis of variance with multiple comparisons. *p&#x0003c;0.05, **p&#x0003c;0.01, ***p&#x0003c;0.001. CSBP, CD24/Siglec-10 blocking peptide; G-MDSC, granulocytic myeloid-derived suppressor cell; IFN, interferon; i.p., intraperitoneally; M-MDSC, monocytic myeloid-derived suppressor cell; PD-L1, programmed death ligand 1; PMA, phorbol 12-myristate 13-acetate; TME, tumor microenvironment.</p></div></div></div></div><div id="s3-6" class="sec"><h3 id="s3-6title">The antitumor effect of CSBP is partially dependent on macrophages</h3><p class="p p-first-last">To investigate the importance of macrophages in antitumor response, clodronate liposomes were used to deplete macrophages in MC38 tumor-bearing mice. In comparison with control liposome, macrophages have shown to be effectively removed from the peripheral blood with clodronate liposome (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S6</a>). The schedule of administration of clodronate liposome or control liposome was shown in <a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S7A</a>. Depletion of macrophages partially abolished the antitumor effect by CSBP treatment (p&#x0003c;0.001, ctrl plus control liposome vs CSBP plus control liposome; p=0.086, ctrl plus clodronate liposome vs CSBP plus clodronate liposome) (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S7B</a>). When macrophages were depleted, the increase of the percentage of tumor infiltrated CD8<sup>+</sup> T cells was not significantly changed after CSBP treatment (p&#x0003c;0.001, ctrl plus control liposome vs CSBP plus control liposome; p=0.0027, ctrl plus clodronate liposome vs CSBP plus clodronate liposome), and the increase of the percentage of tumor infiltrated IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells ratio exhibited slight decrease (p=0.1148, ctrl plus control liposome vs CSBP plus control liposome; p=0.4135, ctrl plus clodronate liposome vs CSBP plus clodronate liposome) (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S7C, D</a>). Furthermore, when macrophages were depleted, the ratio of M-MDSCs was not significantly affected with CSBP treatment (p=0.1059, ctrl plus control liposome vs CSBP plus control liposome; p=0.8744, ctrl plus clodronate liposome vs CSBP plus clodronate liposome) (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S7E</a>). When macrophages were depleted, the increase of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells with CSBP treatment in draining lymph nodes and spleens was slightly impaired, especially in the lymph nodes (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S7F, G</a>). The data suggested that the antitumor effect of CSBP was partially dependent on macrophages.</p></div><div id="s3-7" class="sec"><h3 id="s3-7title">M-MDSCs play an important role in the antitumor effect of CSBP</h3><p class="p p-first-last">To further delineate the role of M-MDSC in the antitumor effects of CSBP, myeloid-derived suppressor cell (MDSC) depletion experiments were performed in MC38 tumor model using the anti-Ly6G/Ly6C (Gr-1) antibody. When C57BL/6 mice were treated with the anti-Ly6G/Ly6C (Gr-1) antibody, there was an efficient depletion of G-MDSCs and M-MDSCs compared with the control IgG (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S8</a>). The schedule of dosing was shown in <a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S9A</a>. Depletion of M-MDSCs significantly attenuated the antitumor effect of CSBP, but the statistical difference did not change (p&#x0003c;0.0001, ctrl plus rat IgG vs CSBP plus rat IgG; p&#x0003c;0.0001, ctrl plus anti-Gr-1 vs CSBP plus anti-Gr-1) (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S9B</a>). When M-MDSCs were depleted, the increase of the percentage of tumor infiltrated CD8<sup>+</sup> T cells was slightly impaired (p=0.0115, ctrl plus rat IgG vs CSBP plus rat IgG; p=0.6287, ctrl plus anti-Gr-1 vs CSBP plus anti-Gr-1), and the ratio of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells was not significantly changed after CSBP treatment (p=0.0103, ctrl plus rat IgG vs CSBP plus rat IgG; p=0.0401, ctrl plus anti-Gr-1 vs CSBP plus anti-Gr-1) (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S9C, D</a>). Furthermore, the ratio of M1/M2 was slightly increased with CSBP treatment after M-MDSCs were depleted (p=0.0855, ctrl plus rat IgG vs CSBP plus rat IgG; p=0.9113, ctrl plus anti-Gr-1 vs CSBP plus anti-Gr-1) (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S9E</a>). When M-MDSCs were depleted, the percentage of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells was increased after CSBP treatment in spleens but not in draining lymph nodes (<a href="#SP1" rid="SP1" class=" supplementary-material">online supplemental figure S9F, G</a>). The data showed that M-MDSCs played an important role in the antitumor effect of CSBP.</p></div><div id="s3-8" class="sec"><h3 id="s3-8title">CSBP combined with radiotherapy exerts synergistically antitumor effect in MC38 tumor model</h3><p class="p p-first">We verified that CSBP targeting PD-1/PD-L1 showed excellent antitumor effect. In addition, RT can recruit tumor immune cells and upregulate PD-L1 expression.<a href="#R30" rid="R30" class=" bibr popnode">30</a> To investigate the therapeutic potential of CSBP combined with local RT, C57BL/6 mice with MC38 tumors were treated with 20&#x02009;Gy once, and CSBP was administered by <em>i.p</em>. injection daily for 2 weeks (<a href="/pmc/articles/PMC10314633/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>figure 5A</span></a>). Compared with the negative control, CSBP treatment or local RT showed a mildly delayed tumor growth. However, the combination treatment of RT and CSBP resulted in a dramatic tumor growth regression compared with monotherapy (<a href="/pmc/articles/PMC10314633/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>figure 5B</span></a>). The proportion of CD8<sup>+</sup> T cells and IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells from tumor infiltrating lymphocytes (TILs) was remarkably increased after CSBP or RT treatment (<a href="/pmc/articles/PMC10314633/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>figure 5C, D</span></a>), and the combination of RT and CSBP treatment enhanced T-cell response. Moreover, we observed that the ratio of M1/M2 macrophages was increased by RT and/or CSBP treatment (<a href="/pmc/articles/PMC10314633/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>figure 5E</span></a>). Interestingly, combination of RT and/or CSBP treatment induced the local accumulation of M-MDSCs (<a href="/pmc/articles/PMC10314633/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>figure 5F</span></a>), consistent with the M-MDSCs phagocytosis results as described above. While, the ratio of G-MDSCs was unaffected (data were not shown). A significantly increased amount of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells in the draining lymph nodes and spleens of tumor-bearing mice was also observed (<a href="/pmc/articles/PMC10314633/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>figure 5G, H</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F5" co-legend-rid="lgnd_F5"><a href="/pmc/articles/PMC10314633/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139632901815136"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10314633_jitc-2023-007068f05.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is jitc-2023-007068f05.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10314633/bin/jitc-2023-007068f05.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139632901815136"><a target="object" rel="noopener" href="/pmc/articles/PMC10314633/figure/F5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F5"><div><a class="figpopup" href="/pmc/articles/PMC10314633/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5">Figure 5</a></div><!--caption a7--><div class="caption"><p>CSBP and RT synergistically amplify the antitumor effect in the MC38 model. (A) Schematic of the dosing schedule time points for treatment groups. (B) The tumor growth curves of MC38-bearing mice receiving the treatment of CSBP and/or RT. Data are presented as the means&#x000b1;SEM (n=5 per group). (C) The percentage of tumor-infiltrating CD8<sup>+</sup> T cells in total CD45<sup>+</sup> cells was determined (n=5). (D) The frequency of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells was detected by flow cytometry (n=5). (E) Flow cytometric analysis of M1/M2 ratio in the TME after CSBP and/or RT treatment (n=5). M1, CD45<sup>+</sup> CD11b<sup>+</sup> F4/80<sup>+</sup> CD11c<sup>+</sup> CD206<sup>&#x02212;</sup>; M2, CD45<sup>+</sup> CD11b<sup>+</sup> F4/80<sup>+</sup> CD206<sup>+</sup> CD11c<sup>&#x02212;</sup>. (F) Percentages of myeloid-derived suppressor cell within the TME in each group (n=5). G-MDSC, CD45<sup>+</sup> CD11b<sup>+</sup> Ly6G<sup>+</sup> Ly6C<sup>&#x02212;</sup>; M-MDSC, CD45<sup>+</sup> CD11b<sup>+</sup> Ly6G<sup>&#x02212;</sup> Ly6C<sup>+</sup>. (G, H) Cells from mice draining lymph nodes (G) or spleens (H) were obtained and stimulated with 20&#x02009;ng/mL of PMA and 1&#x02009;&#x000b5;M ionomycin containing protein transport inhibitor cocktail for 4&#x02009;hours. Frequencies of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells were detected by flow cytometry (n=5). Data are presented as means&#x000b1;SEM, and statistical significance was determined by two-way analysis of variance with multiple comparisons. <em>*</em>p&#x0003c;0.05, <em>**</em>p&#x0003c;0.01, <em>***</em>p&#x0003c;0.001. CSBP, CD24/Siglec-10 blocking peptide; G-MDSC, granulocytic myeloid-derived suppressor cell; IFN, interferon; i.p., intraperitoneally; M-MDSC, monocytic myeloid-derived suppressor cell; PMA, phorbol 12-myristate 13-acetate; RT, radiotherapy; TME, tumor microenvironment.</p></div></div></div></div><div id="s3-9" class="sec sec-last"><h3 id="s3-9title">CSBP combined with RT enhances antitumor activity in anti-PD-1&#x02013;resistant 4T1 tumor model</h3><p class="p p-first">The mouse mammary carcinoma 4T1 model is a well-characterized model of cold, poorly immunogenic, and anti-PD-1&#x02013;resistant tumor model. In this model, we explored whether adding RT to CSBP treatment would increase antitumor immunity. The design of the experiment was shown in <a href="/pmc/articles/PMC10314633/figure/F6/" target="figure" class="fig-table-link figpopup" rid-figpopup="F6" rid-ob="ob-F6" co-legend-rid="lgnd_F6"><span>figure 6A</span></a>, BALB/c mice with 4T1 tumors were treated with the dosage of 12&#x02009;Gy for twice, and then CSBP was administrated by <em>i.p</em>. injection daily. Mice had less tumor burden with CSBP and/or RT treatment relative to the negative control (<a href="/pmc/articles/PMC10314633/figure/F6/" target="figure" class="fig-table-link figpopup" rid-figpopup="F6" rid-ob="ob-F6" co-legend-rid="lgnd_F6"><span>figure 6B</span></a>). Similar to the results investigated above, the proportion of tumor-infiltrating CD8<sup>+</sup> T cells and M-MDSCs, and the M1/M2 macrophage ratio were increased. Significantly enhanced amount of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells from TILs, the draining lymph nodes and spleens of tumor-bearing mice was detected (<a href="/pmc/articles/PMC10314633/figure/F6/" target="figure" class="fig-table-link figpopup" rid-figpopup="F6" rid-ob="ob-F6" co-legend-rid="lgnd_F6"><span>figure 6C&#x02013;H</span></a>). These results suggested that CSBP might have great potential to overcome PD-1 blockade resistance.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F6" co-legend-rid="lgnd_F6"><a href="/pmc/articles/PMC10314633/figure/F6/" target="figure" rid-figpopup="F6" rid-ob="ob-F6"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139632898410688"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10314633_jitc-2023-007068f06.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is jitc-2023-007068f06.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10314633/bin/jitc-2023-007068f06.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139632898410688"><a target="object" rel="noopener" href="/pmc/articles/PMC10314633/figure/F6/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F6"><div><a class="figpopup" href="/pmc/articles/PMC10314633/figure/F6/" target="figure" rid-figpopup="F6" rid-ob="ob-F6">Figure 6</a></div><!--caption a7--><div class="caption"><p>CSBP enhances antitumor efficacy combined with RT in the 4T1 tumor model. (A) Treatment schedules and dosing. (B) 4T1 tumor growth following CSBP and/or RT treatment in vivo. Data are presented as the means&#x000b1;SEM (n=5 per group). (C) Flow cytometric analysis of CD8<sup>+</sup> T cells on CD45<sup>+</sup> cells in each group (n=5). (D) The frequency of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells was detected by flow cytometry (n=5). (E, F) Quantitative data of the M1/M2 ratio and the percentage of myeloid-derived suppressor cells relative to CD45<sup>+</sup> cells in each group (n=5). M1, CD45<sup>+</sup> CD11b<sup>+</sup> F4/80<sup>+</sup> CD11c<sup>+</sup> CD206<sup>&#x02212;</sup>; M2, CD45<sup>+</sup> CD11b<sup>+</sup> F4/80<sup>+</sup> CD206<sup>+</sup> CD11c<sup>&#x02212;</sup>; G-MDSC, CD45<sup>+</sup> CD11b<sup>+</sup> Ly6G<sup>+</sup> Ly6C<sup>&#x02212;</sup>; M-MDSC, CD45<sup>+</sup> CD11b<sup>+</sup> Ly6G<sup>&#x02212;</sup> Ly6C<sup>+</sup>. (G, H) Cells from mice draining lymph nodes (G) or spleens (H) were obtained and stimulated with 20&#x02009;ng/mL of PMA and 1&#x02009;&#x000b5;M ionomycin containing protein transport inhibitor cocktail for 4&#x02009;hours. Frequencies of IFN-&#x003b3;-expressing CD8<sup>+</sup> T cells were detected by flow cytometry (n=5). Data are presented as means&#x000b1;SEM, and statistical significance was determined by two-way analysis of variance with multiple comparisons. *p&#x0003c;0.05, **p&#x0003c;0.01, ***p&#x0003c;0.001. CSBP, CD24/Siglec-10 blocking peptide; G-MDSC, granulocytic myeloid-derived suppressor cell; IFN, interferon; i.p., intraperitoneally; M-MDSC, monocytic myeloid-derived suppressor cell; PMA, phorbol 12-myristate 13-acetate; RT, radiotherapy; TME, tumor microenvironment.</p></div></div></div></div></div><div id="s4" class="tsec sec"><h2 class="head no_bottom_margin" id="s4title">Discussion</h2><p class="p p-first">Clinical studies have demonstrated that more than 75% of patients with cancer failed to respond to ICI therapy.<a href="#R31" rid="R31" class=" bibr popnode">31</a> Moreover, PD-L1 expression level is not sufficient to be a clinical predictor, as some patients with PD-L1-expressing tumors do not respond to anti-PD-1 or anti-PD-L1 therapy, while some patients with PD-L1-negative tumors may be responsive. In this study, gene expression analysis suggested that the CD24 expression was much higher than PD-L1 in most BRCA subclasses, and single-cell RNA-sequencing data demonstrated that CD24 was expressed higher than PD-L1 in both T-cell expansion and T-cell non-expansion after anti-PD-1 treatment. The results inspired us to further investigate the potential of targeting CD24 to improve ICB response in cancer types with low-expression of the PD-L1.</p><p>Recent studies have shown that CD24/Siglec-10 delayed anti-phagocytic signals. Compared with the conventional anti-phagocytic signal CD47-Sirp&#x003b1;, the extensive expression of CD47 on normal tissues and cells, particularly red blood cells (RBCs), significantly increased risk of toxicity by using anti-CD47 therapeutic antibodies.<a href="#R6" rid="R6" class=" bibr popnode">6</a> Based on our data showing that CD24 is rarely expressed on normal cells and human erythrocytes, thus, CD24 can act as a therapeutic target with higher safety. Our data indicated that CD24 blockade enhanced macrophage-mediated phagocytosis of tumor cells in concordance with previous work that anti-CD24 mAb treatment enhanced phagocytic clearance of tumor cells.<a href="#R8" rid="R8" class=" bibr popnode">8</a> However, how macrophages enhance antitumor effects with CD24 blockade has not been adequately investigated in the current studies. Our results illustrated macrophages primed CD8<sup>+</sup> T cells by phagocytosis of tumor cells after CSBP treatment. This role is consistent with the previous studies that macrophages as the antigen-presenting cells (APCs) that phagocytose tumor cells and present antigens to CD8<sup>+</sup> T cells in response to anti-CD47 antibodies.<a href="#R32" rid="R32" class=" bibr popnode">32</a> CD24 and PD-L1, are considered as critical innate and adaptive checkpoints, which are extremely important for the antitumor immune response. Simultaneously targeting CD24/Siglec-10 and PD-1/PD-L1 signals is a promising strategy to reshape immunosuppressive tumor microenvironment (TME) and potentiate host innate and adaptive antitumor immune responses. Notably, there are few studies on the simultaneous blocking of CD24 and PD-L1, and most of the CD24 or PD-L1 inhibitors are analyzed using monoclonal antibodies, which only activate macrophages or T cells. In the MC38 tumor model, compared with anti-PD-L1 monotherapy, treatment with anti-PD-L1 plus anti-CD24 as well as CSBP showed better antitumor effect, but they did not produce statistically significant effect. These results may be explained by the fact that PD-L1 is expressed on both T cells and macrophages, and anti-PD-L1 treatment enables activation of T cells and promotion of macrophage-mediated phagocytosis of tumor cells.<a href="#R33" rid="R33" class=" bibr popnode">33 34</a> The treatment of anti-PD-L1 plus anti-CD24 as well as CSBP simultaneously targeting PD-L1 and CD24 also activated T cells and enhanced macrophage phagocytosis, so the effect was not significant. Although the antitumor effect of CSBP was not as potent as anti-PD-L1, CSBP dual-targeting CD24 and PD-L1 could target tumor sites with higher specificity to exert antitumor activity. Considering that the antitumor response of CSBP might involve reshaping the TME, we examined the effect of CSBP on the immune cells of TME. As a result, CSBP substantially increased the ratios of TILs and M-MDSCs, increased the ratio of M1/M2, and enhanced the effector function of CD8<sup>+</sup> T cells. By depletion of macrophages or M-MDSCs in the MC38 tumor model, the results demonstrated CSBP exerted antitumor effects partially depending on the function of macrophages and M-MDSCs.</p><p>Our study has discovered the vital coordination between tumor-cell-relation CD24 and PD-L1 for tumor evasion. It was reported that dosing RT prior to ICB could result in a systemic antitumor response.<a href="#R35" rid="R35" class=" bibr popnode">35</a> Radiation mediates localized tumor killing and TME modification, thereby potentiating the action of ICB.<a href="#R35" rid="R35" class=" bibr popnode">35</a> We speculated that the synergistic effects of RT combined with CSBP peptide might due to the following reasons. (1) RT can induce a local antitumor immune response by recruiting tumor-specific T cells and simultaneously increase PD-L1 expression, while the subsequent PD-1/PD-L1 blockade might amplify the antitumor response.<a href="#R30" rid="R30" class=" bibr popnode">30 36</a> CSBP can act as a PD-1/PD-L1 inhibitor, thus combining RT to CSBP treatment can boost the antitumor effectiveness. (2) RT stimulates the recruitment of macrophages to the TME. Macrophages in response to inflammatory signals produced by irradiation and are locally activated to phagocytose tumor cells.<a href="#R37" rid="R37" class=" bibr popnode">37</a> Our results indicated that CSBP could increase the number of M1 macrophages and M1/M2 ratio. These inflammatory macrophages were used by CSBP with phagocytic capacity toward tumor cells. (3) Radiation increases the infiltration of MDSCs.<a href="#R38" rid="R38" class=" bibr popnode">38</a> Surprisingly, it was found that M-MDSCs could also phagocytose tumor cells after CSBP treatment. Thus, RT combined with CSBP treatment is superior to monotherapy.</p><p>In addition to macrophages and CD8<sup>+</sup> T cells, we found that the proportion of M-MDSC also revealed a dramatic increase following CSBP treatment or combination treatment with RT, but no significant change in G-MDSC. Previous studies found that MDSCs were a heterogeneous group of pathologically expanded myeloid cells. MDSCs suppress cytotoxic T cells and decline their antitumor activity by releasing reactive oxygen species and related cytokines.<a href="#R39" rid="R39" class=" bibr popnode">39</a> Studies revealed that elevated MDSCs were responsible for the resistance in anti-PD-1 or anti-cytotoxic T Lymphocyte antigen 4 (CTLA-4) treatment, and elimination of MDSCs could lead to cures of metastatic tumors.<a href="#R40" rid="R40" class=" bibr popnode">40</a> In this study, we found that mouse Siglec-G was overexpressed in MDSCs in mice, indicating that CD24/Siglec-10 might be a vital role of MDSC-mediated tumor cell clearance. Indeed, we observed that in vitro CD24 blockade enhanced M-MDSC-mediated phagocytosis to tumor cells, in vivo M-MDSCs were upregulated with the combination of CSBP and RT. Our work described the role for MDSCs in phagocytosis of tumor cells, and the findings differ from previous studies. However, as a heterogeneous population of myeloid cells, MDSCs possess phagocytic potential.<a href="#R41" rid="R41" class=" bibr popnode">41</a> A number of research studies found that G-MDSCs isolated from tumor-bearing mice could phagocytose latex beads. And previous work suggested that G-MDSCs were able to phagocytose both gram-negative and gram-positive bacteria, in common with PMN-MDSCs from tumor-bearing (cancer) dogs (C-PMNs). <a href="#R42" rid="R42" class=" bibr popnode">42</a> In fact, these are some common features between MDSCs and immature dendritic cells, such as low expression of MHC class II and antigen uptake capacity.<a href="#R43" rid="R43" class=" bibr popnode">43</a> These results proved our hypothesis that there is a novel functional link between M-MDSCs and the efficacy of antitumor immunity. Simultaneously, we initially observed that there were no abnormalities in major organs, including heart, liver, spleen, lung and kidney, and no significant differences in red blood cell count, hemoglobin level, alanine transaminase (ALT) and aspartate transaminase (AST) levels after CSBP treatment in 4T1 and MC38 tumor models. It may require pharmacokinetics studies to further assess the in vivo safety profile of CSBP.</p><p class="p">Taken together, our study found a CD24 and PD-L1 dual-blockade peptide, CSBP, which targeted CD24<sup>+</sup> or/and PD-L1<sup>+</sup> tumor cells while minimizing on-target toxicities in normal tissues. CSBP could improve cancer immunotherapy with high therapeutic efficacy by harnessing both innate and adaptive immune responses. In addition, our work described a previously uncharacterized mechanism that M-MDSC-mediated phagocytosis of tumor cells promoted potent antitumor activity. We found that CSBP and RT combination therapy exerted a synergistically antitumor effect. We believe the therapeutic approach holds promising potential to reshape the immunosuppressive tumor environment and provides new insights into the design of new therapeutics for immunotherapy.</p><div class="sec suppmat" id="SP2"><h4>Supplementary data</h4><p>
<a href="/pmc/articles/PMC10314633/bin/jitc-2023-007068supp002.pdf" id="SS2">jitc-2023-007068supp002.pdf</a>
</p></div></div><div id="ack-a.m.a" class="tsec sec"><h2 class="head no_bottom_margin" id="ack-a.m.atitle">Acknowledgments</h2><div class="sec"><p>We thank all the laboratory members for helping with the experiments.</p></div></div><div id="fn-group-a.m.b" class="tsec sec"><h2 class="head no_bottom_margin" id="fn-group-a.m.btitle">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="fn-a.m.b.a"><p class="p p-first-last"><strong>Contributors:</strong> WS and YG designed the study. WS, PS, QD, and CC performed the experiments. WT, XZhu, XW, and SJ analyzed the data. XZhou, XS, YW, GC, and LQ provided advice. WS, WZ, and YG wrote and revised the manuscript. All authors read and approved the final manuscript. WZ and YG are responsible for the overall content, had access to the data and controlled the decision to publish.</p></p><p class="fn sec" id="fn-a.m.b.b"><p class="p p-first-last"><strong>Funding:</strong> This work was supported by grants from the National Natural Science Foundation of China (U20A20369), Shenzhen Science and Technology Program (KQTD20190929173853397), &#x0201c;Pearl River Talent Plan&#x0201d; Innovation and Entrepreneurship Team Project of Guangdong Province (2019ZT08Y464) and Guangdong Basic and Applied Basic Research Foundation (2022B1515120085).</p></p><p class="fn sec" id="fn-a.m.b.c"><p class="p p-first-last"><strong>Competing interests:</strong> None declared.</p></p><p class="fn sec" id="fn-a.m.b.d"><p class="p p-first-last"><strong>Provenance and peer review:</strong> Not commissioned; externally peer reviewed.</p></p><p class="fn sec" id="fn-a.m.b.e"><p class="p p-first-last"><strong>Supplemental material:</strong> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></p></div></div><div id="sec-a.m.c" class="tsec bk-sec"><h2 class="head no_bottom_margin" id="sec-a.m.ctitle">Data availability statement</h2><!--/article/back/sec/--><p class="p p-first-last">Data are available upon reasonable request.</p></div><div id="sec-a.m.d" class="tsec bk-sec"><h2 class="head no_bottom_margin" id="sec-a.m.dtitle">Ethics statements</h2><!--/article/back/sec/--><div id="sec-a.m.d.b" class="sec sec-first"><h3 id="sec-a.m.d.btitle">Patient consent for publication</h3><p class="p p-first-last">Not applicable.</p></div><div id="sec-a.m.d.c" class="sec sec-last"><h3 id="sec-a.m.d.ctitle">Ethics approval</h3><p class="p p-first-last">Animal study was approved by the Ethics Committee of Sun Yat-sen University. The ethical approval number was SYSU-20200437.</p></div></div><div id="ref-list-a.m.e" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.m.etitle">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="mixed-citation">
Lesch S, Gill S. <span class="ref-title">The promise and perils of Immunotherapy</span>. <span class="ref-journal">Blood Adv</span>
2021;<span class="ref-vol">5</span>:3709&#x02013;25. 10.1182/bloodadvances.2021004453C
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8945582/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34581774" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1182%2Fbloodadvances.2021004453C" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood+Adv&amp;title=The+promise+and+perils+of+Immunotherapy&amp;volume=5&amp;publication_year=2021&amp;pages=3709-25&amp;pmid=34581774&amp;doi=10.1182/bloodadvances.2021004453C&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="mixed-citation">
Zaretsky JM, Garcia-Diaz A, Shin DS, et al.. <span class="ref-title">Mutations associated with acquired resistance to PD-1 blockade in Melanoma</span>. <span class="ref-journal">N Engl J Med</span>
2016;<span class="ref-vol">375</span>:819&#x02013;29. 10.1056/NEJMoa1604958
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5007206/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27433843" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1056%2FNEJMoa1604958" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Mutations+associated+with+acquired+resistance+to+PD-1+blockade+in+Melanoma&amp;volume=375&amp;publication_year=2016&amp;pages=819-29&amp;pmid=27433843&amp;doi=10.1056/NEJMoa1604958&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="mixed-citation">
Zhang S-Y, Song X-Y, Li Y, et al.. <span class="ref-title">Tumor-associated Macrophages: A promising target for a cancer Immunotherapeutic strategy</span>. <span class="ref-journal">Pharmacol Res</span>
2020;<span class="ref-vol">161</span>:S1043-6618(20)31419-5. 10.1016/j.phrs.2020.105111
 [<a href="https://pubmed.ncbi.nlm.nih.gov/33065284" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.phrs.2020.105111" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacol+Res&amp;title=Tumor-associated+Macrophages:+A+promising+target+for+a+cancer+Immunotherapeutic+strategy&amp;volume=161&amp;publication_year=2020&amp;pages=S1043-6618(20)31419-5&amp;doi=10.1016/j.phrs.2020.105111&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="mixed-citation">
Muntjewerff EM, Meesters LD, van den Bogaart G. <span class="ref-title">Antigen cross-presentation by Macrophages</span>. <span class="ref-journal">Front Immunol</span>
2020;<span class="ref-vol">11</span>:1276. 10.3389/fimmu.2020.01276
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7360722/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32733446" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffimmu.2020.01276" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Immunol&amp;title=Antigen+cross-presentation+by+Macrophages&amp;volume=11&amp;publication_year=2020&amp;pages=1276&amp;pmid=32733446&amp;doi=10.3389/fimmu.2020.01276&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="mixed-citation">
Sikic BI, Lakhani N, Patnaik A, et al.. <span class="ref-title">First-in-human, first-in-class phase I trial of the anti-Cd47 antibody Hu5F9-G4 in patients with advanced cancers</span>. <span class="ref-journal">J Clin Oncol</span>
2019;<span class="ref-vol">37</span>:946&#x02013;53. 10.1200/JCO.18.02018
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7186585/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30811285" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1200%2FJCO.18.02018" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=First-in-human,+first-in-class+phase+I+trial+of+the+anti-Cd47+antibody+Hu5F9-G4+in+patients+with+advanced+cancers&amp;volume=37&amp;publication_year=2019&amp;pages=946-53&amp;pmid=30811285&amp;doi=10.1200/JCO.18.02018&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="mixed-citation">
Advani R, Flinn I, Popplewell L, et al.. <span class="ref-title">Cd47 blockade by Hu5F9-G4 and Rituximab in non-Hodgkin&#x02019;s lymphoma</span>. <span class="ref-journal">N Engl J Med</span>
2018;<span class="ref-vol">379</span>:1711&#x02013;21. 10.1056/NEJMoa1807315
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8058634/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30380386" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1056%2FNEJMoa1807315" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Cd47+blockade+by+Hu5F9-G4+and+Rituximab+in+non-Hodgkin&#x02019;s+lymphoma&amp;volume=379&amp;publication_year=2018&amp;pages=1711-21&amp;pmid=30380386&amp;doi=10.1056/NEJMoa1807315&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="mixed-citation">
Wang H, Sun Y, Zhou X, et al.. <span class="ref-title">Cd47/Sirpalpha blocking peptide identification and synergistic effect with irradiation for cancer Immunotherapy</span>. <span class="ref-journal">J Immunother Cancer</span>
2020;<span class="ref-vol">8</span>:e000905. 10.1136/jitc-2020-000905
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7537338/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33020240" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1136%2Fjitc-2020-000905" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunother+Cancer&amp;title=Cd47/Sirpalpha+blocking+peptide+identification+and+synergistic+effect+with+irradiation+for+cancer+Immunotherapy&amp;volume=8&amp;publication_year=2020&amp;pages=e000905&amp;pmid=33020240&amp;doi=10.1136/jitc-2020-000905&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="mixed-citation">
Barkal AA, Brewer RE, Markovic M, et al.. <span class="ref-title">Cd24 signalling through macrophage Siglec-10 is a target for cancer Immunotherapy</span>. <span class="ref-journal">Nature</span>
2019;<span class="ref-vol">572</span>:392&#x02013;6. 10.1038/s41586-019-1456-0
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6697206/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31367043" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41586-019-1456-0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Cd24+signalling+through+macrophage+Siglec-10+is+a+target+for+cancer+Immunotherapy&amp;volume=572&amp;publication_year=2019&amp;pages=392-6&amp;pmid=31367043&amp;doi=10.1038/s41586-019-1456-0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="mixed-citation">
Hardy RR, Hayakawa K, Parks DR, et al.. <span class="ref-title">Murine B cell differentiation lineages</span>. <span class="ref-journal">J Exp Med</span>
1984;<span class="ref-vol">159</span>:1169&#x02013;88. 10.1084/jem.159.4.1169
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2187278/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6423764" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1084%2Fjem.159.4.1169" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Exp+Med&amp;title=Murine+B+cell+differentiation+lineages&amp;volume=159&amp;publication_year=1984&amp;pages=1169-88&amp;pmid=6423764&amp;doi=10.1084/jem.159.4.1169&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="mixed-citation">
Crispe IN, Bevan MJ. <span class="ref-title">Expression and functional significance of the J11D marker on mouse Thymocytes</span>. <span class="ref-journal">J Immunol</span>
1987;<span class="ref-vol">138</span>:2013&#x02013;8. 10.4049/jimmunol.138.7.2013
 [<a href="https://pubmed.ncbi.nlm.nih.gov/2435787" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.138.7.2013" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Expression+and+functional+significance+of+the+J11D+marker+on+mouse+Thymocytes&amp;volume=138&amp;publication_year=1987&amp;pages=2013-8&amp;pmid=2435787&amp;doi=10.4049/jimmunol.138.7.2013&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="mixed-citation">
Williams LA, Hock BD, Hart DN. <span class="ref-title">Human T lymphocytes and hematopoietic cell lines Express Cd24-associated carbohydrate Epitopes in the absence of Cd24 mRNA or protein</span>. <span class="ref-journal">Blood</span>
1996;<span class="ref-vol">88</span>:3048&#x02013;55. [<a href="https://pubmed.ncbi.nlm.nih.gov/8874203" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Human+T+lymphocytes+and+hematopoietic+cell+lines+Express+Cd24-associated+carbohydrate+Epitopes+in+the+absence+of+Cd24+mRNA+or+protein&amp;volume=88&amp;publication_year=1996&amp;pages=3048-55&amp;pmid=8874203&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="mixed-citation">
Nielsen PJ, Lorenz B, M&#x000fc;ller AM, et al.. <span class="ref-title">Altered Erythrocytes and a leaky block in B-cell development in Cd24/HSA-deficient mice</span>. <span class="ref-journal">Blood</span>
1997;<span class="ref-vol">89</span>:1058&#x02013;67. [<a href="https://pubmed.ncbi.nlm.nih.gov/9028339" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Altered+Erythrocytes+and+a+leaky+block+in+B-cell+development+in+Cd24/HSA-deficient+mice&amp;volume=89&amp;publication_year=1997&amp;pages=1058-67&amp;pmid=9028339&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="mixed-citation">
Li O, Zheng P, Liu Y. <span class="ref-title">Cd24 expression on T cells is required for optimal T cell proliferation in Lymphopenic host</span>. <span class="ref-journal">J Exp Med</span>
2004;<span class="ref-vol">200</span>:1083&#x02013;9. 10.1084/jem.20040779
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2211842/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15477346" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1084%2Fjem.20040779" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Exp+Med&amp;title=Cd24+expression+on+T+cells+is+required+for+optimal+T+cell+proliferation+in+Lymphopenic+host&amp;volume=200&amp;publication_year=2004&amp;pages=1083-9&amp;pmid=15477346&amp;doi=10.1084/jem.20040779&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="mixed-citation">
Tarhriz V, Bandehpour M, Dastmalchi S, et al.. <span class="ref-title">Overview of Cd24 as a new molecular marker in ovarian cancer</span>. <span class="ref-journal">Journal Cellular Physiology</span>
2019;<span class="ref-vol">234</span>:2134&#x02013;42. 10.1002/jcp.27581
Available: <a href="https://onlinelibrary.wiley.com/toc/10974652/234/3">https://onlinelibrary.wiley.com/toc/10974652/234/3</a>
 [<a href="https://pubmed.ncbi.nlm.nih.gov/30317611" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fjcp.27581" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+Cellular+Physiology&amp;title=Overview+of+Cd24+as+a+new+molecular+marker+in+ovarian+cancer&amp;volume=234&amp;publication_year=2019&amp;pages=2134-42&amp;doi=10.1002/jcp.27581&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="mixed-citation">
Qiao X-J, Gu Y, Du H, et al.. <span class="ref-title">Co-expression of Cd24 and Hsp70 as a Prognostic biomarker for lung cancer</span>. <span class="ref-journal">Neoplasma</span>
2021;<span class="ref-vol">68</span>:1023&#x02013;32. 10.4149/neo_2021_210118N81
 [<a href="https://pubmed.ncbi.nlm.nih.gov/34427097" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4149%2Fneo_2021_210118N81" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neoplasma&amp;title=Co-expression+of+Cd24+and+Hsp70+as+a+Prognostic+biomarker+for+lung+cancer&amp;volume=68&amp;publication_year=2021&amp;pages=1023-32&amp;pmid=34427097&amp;doi=10.4149/neo_2021_210118N81&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="mixed-citation">
Barash U, Spyrou A, Liu P, et al.. <span class="ref-title">Heparanase promotes glioma progression via enhancing Cd24 expression</span>. <span class="ref-journal">Int J Cancer</span>
2019;<span class="ref-vol">145</span>:1596&#x02013;608. 10.1002/ijc.32375
 [<a href="https://pubmed.ncbi.nlm.nih.gov/31032901" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fijc.32375" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Cancer&amp;title=Heparanase+promotes+glioma+progression+via+enhancing+Cd24+expression&amp;volume=145&amp;publication_year=2019&amp;pages=1596-608&amp;pmid=31032901&amp;doi=10.1002/ijc.32375&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="mixed-citation">
Zhou Z, Li Y, Kuang M, et al.. <span class="ref-title">The Cd24(+) cell subset promotes invasion and metastasis in human Osteosarcoma</span>. <span class="ref-journal">EBioMedicine</span>
2020;<span class="ref-vol">51</span>:102598. 10.1016/j.ebiom.2019.102598
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6948162/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31901872" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ebiom.2019.102598" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=EBioMedicine&amp;title=The+Cd24(+)+cell+subset+promotes+invasion+and+metastasis+in+human+Osteosarcoma&amp;volume=51&amp;publication_year=2020&amp;pages=102598&amp;pmid=31901872&amp;doi=10.1016/j.ebiom.2019.102598&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="mixed-citation">
Salnikov AV, Bretz NP, Perne C, et al.. <span class="ref-title">Antibody targeting of Cd24 efficiently Retards growth and influences cytokine milieu in experimental Carcinomas</span>. <span class="ref-journal">Br J Cancer</span>
2013;<span class="ref-vol">108</span>:1449&#x02013;59. 10.1038/bjc.2013.102
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3629417/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23511563" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fbjc.2013.102" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Cancer&amp;title=Antibody+targeting+of+Cd24+efficiently+Retards+growth+and+influences+cytokine+milieu+in+experimental+Carcinomas&amp;volume=108&amp;publication_year=2013&amp;pages=1449-59&amp;pmid=23511563&amp;doi=10.1038/bjc.2013.102&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="mixed-citation">
Chan S-H, Tsai K-W, Chiu S-Y, et al.. <span class="ref-title">Identification of the novel role of Cd24 as an Oncogenesis regulator and therapeutic target for triple-negative breast cancer</span>. <span class="ref-journal">Mol Cancer Ther</span>
2019;<span class="ref-vol">18</span>:147&#x02013;61. 10.1158/1535-7163.MCT-18-0292
 [<a href="https://pubmed.ncbi.nlm.nih.gov/30381446" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1535-7163.MCT-18-0292" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Identification+of+the+novel+role+of+Cd24+as+an+Oncogenesis+regulator+and+therapeutic+target+for+triple-negative+breast+cancer&amp;volume=18&amp;publication_year=2019&amp;pages=147-61&amp;pmid=30381446&amp;doi=10.1158/1535-7163.MCT-18-0292&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="mixed-citation">
Conibear AC, Schmid A, Kamalov M, et al.. <span class="ref-title">Recent advances in peptide-based approaches for cancer treatment</span>. <span class="ref-journal">Curr Med Chem</span>
2020;<span class="ref-vol">27</span>:1174&#x02013;205. 10.2174/0929867325666171123204851
 [<a href="https://pubmed.ncbi.nlm.nih.gov/29173146" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2174%2F0929867325666171123204851" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr+Med+Chem&amp;title=Recent+advances+in+peptide-based+approaches+for+cancer+treatment&amp;volume=27&amp;publication_year=2020&amp;pages=1174-205&amp;pmid=29173146&amp;doi=10.2174/0929867325666171123204851&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="mixed-citation">
Chang H-N, Liu B-Y, Qi Y-K, et al.. <span class="ref-title">Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer Immunotherapy</span>. <span class="ref-journal">Angew Chem Int Ed Engl</span>
2015;<span class="ref-vol">54</span>:11760&#x02013;4. 10.1002/anie.201506225
 [<a href="https://pubmed.ncbi.nlm.nih.gov/26259671" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fanie.201506225" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Angew+Chem+Int+Ed+Engl&amp;title=Blocking+of+the+PD-1/PD-L1+interaction+by+a+D-peptide+antagonist+for+cancer+Immunotherapy&amp;volume=54&amp;publication_year=2015&amp;pages=11760-4&amp;pmid=26259671&amp;doi=10.1002/anie.201506225&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="mixed-citation">
Zhou X, Zuo C, Li W, et al.. <span class="ref-title">A novel D-peptide identified by mirror-image Phage display blocks TIGIT/PVR for cancer Immunotherapy</span>. <span class="ref-journal">Angew Chem Int Ed Engl</span>
2020;<span class="ref-vol">59</span>:15114&#x02013;8. 10.1002/anie.202002783
Available: <a href="https://onlinelibrary.wiley.com/toc/15213773/59/35">https://onlinelibrary.wiley.com/toc/15213773/59/35</a>
 [<a href="https://pubmed.ncbi.nlm.nih.gov/32386245" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fanie.202002783" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Angew+Chem+Int+Ed+Engl&amp;title=A+novel+D-peptide+identified+by+mirror-image+Phage+display+blocks+TIGIT/PVR+for+cancer+Immunotherapy&amp;volume=59&amp;publication_year=2020&amp;pages=15114-8&amp;pmid=32386245&amp;doi=10.1002/anie.202002783&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="mixed-citation">
Zhai W, Zhou X, Wang H, et al.. <span class="ref-title">A novel cyclic peptide targeting LAG-3 for cancer Immunotherapy by activating antigen-specific Cd8(+) T cell responses</span>. <span class="ref-journal">Acta Pharm Sin B</span>
2020;<span class="ref-vol">10</span>:1047&#x02013;60. 10.1016/j.apsb.2020.01.005
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7332792/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32642411" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.apsb.2020.01.005" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Acta+Pharm+Sin+B&amp;title=A+novel+cyclic+peptide+targeting+LAG-3+for+cancer+Immunotherapy+by+activating+antigen-specific+Cd8(+)+T+cell+responses&amp;volume=10&amp;publication_year=2020&amp;pages=1047-60&amp;pmid=32642411&amp;doi=10.1016/j.apsb.2020.01.005&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="mixed-citation">
Bassez A, Vos H, Van Dyck L, et al.. <span class="ref-title">A single-cell map of Intratumoral changes during anti-Pd1 treatment of patients with breast cancer</span>. <span class="ref-journal">Nat Med</span>
2021;<span class="ref-vol">27</span>:820&#x02013;32. 10.1038/s41591-021-01323-8
 [<a href="https://pubmed.ncbi.nlm.nih.gov/33958794" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41591-021-01323-8" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Med&amp;title=A+single-cell+map+of+Intratumoral+changes+during+anti-Pd1+treatment+of+patients+with+breast+cancer&amp;volume=27&amp;publication_year=2021&amp;pages=820-32&amp;pmid=33958794&amp;doi=10.1038/s41591-021-01323-8&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="mixed-citation">
Migo&#x00144; D, Ja&#x0015b;kiewicz M, Neubauer D, et al.. <span class="ref-title">Alanine scanning studies of the antimicrobial peptide aurein 1.2</span>. <span class="ref-journal">Probiotics &#x00026; Antimicro Prot</span>
2019;<span class="ref-vol">11</span>:1042&#x02013;54. 10.1007/s12602-018-9501-0
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6695355/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30569430" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs12602-018-9501-0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Probiotics+&#x00026;+Antimicro+Prot&amp;title=Alanine+scanning+studies+of+the+antimicrobial+peptide+aurein+1.2&amp;volume=11&amp;publication_year=2019&amp;pages=1042-54&amp;doi=10.1007/s12602-018-9501-0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="mixed-citation">
Lucana MC, Arruga Y, Petrachi E, et al.. <span class="ref-title">Protease-resistant peptides for targeting and intracellular delivery of Therapeutics</span>. <span class="ref-journal">Pharmaceutics</span>
2021;<span class="ref-vol">13</span>:2065. 10.3390/pharmaceutics13122065
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8708026/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34959346" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fpharmaceutics13122065" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmaceutics&amp;title=Protease-resistant+peptides+for+targeting+and+intracellular+delivery+of+Therapeutics&amp;volume=13&amp;publication_year=2021&amp;pages=2065&amp;pmid=34959346&amp;doi=10.3390/pharmaceutics13122065&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="mixed-citation">
Yan L, Ke Y, Kan Y, et al.. <span class="ref-title">New insight into enzymatic hydrolysis of peptides with site-specific amino acid D-isomerization</span>. <span class="ref-journal">Bioorg Chem</span>
2020;<span class="ref-vol">105</span>:S0045-2068(20)31687-4. 10.1016/j.bioorg.2020.104389
 [<a href="https://pubmed.ncbi.nlm.nih.gov/33120320" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.bioorg.2020.104389" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg+Chem&amp;title=New+insight+into+enzymatic+hydrolysis+of+peptides+with+site-specific+amino+acid+D-isomerization&amp;volume=105&amp;publication_year=2020&amp;pages=S0045-2068(20)31687-4&amp;doi=10.1016/j.bioorg.2020.104389&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="mixed-citation">
Shukla D, Trout BL. <span class="ref-title">Understanding the synergistic effect of arginine and glutamic acid mixtures on protein solubility</span>. <span class="ref-journal">J Phys Chem B</span>
2011;<span class="ref-vol">115</span>:11831&#x02013;9. 10.1021/jp204462t
 [<a href="https://pubmed.ncbi.nlm.nih.gov/21894928" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1021%2Fjp204462t" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Phys+Chem+B&amp;title=Understanding+the+synergistic+effect+of+arginine+and+glutamic+acid+mixtures+on+protein+solubility&amp;volume=115&amp;publication_year=2011&amp;pages=11831-9&amp;pmid=21894928&amp;doi=10.1021/jp204462t&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="mixed-citation">
Li W, Zhu X, Zhou X, et al.. <span class="ref-title">An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded Trimethyl Chitosan Hydrogel for cancer Immunotherapy</span>. <span class="ref-journal">J Control Release</span>
2021;<span class="ref-vol">334</span>:376&#x02013;88. 10.1016/j.jconrel.2021.04.036
 [<a href="https://pubmed.ncbi.nlm.nih.gov/33940058" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.jconrel.2021.04.036" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Control+Release&amp;title=An+orally+available+PD-1/PD-L1+blocking+peptide+OPBP-1-loaded+Trimethyl+Chitosan+Hydrogel+for+cancer+Immunotherapy&amp;volume=334&amp;publication_year=2021&amp;pages=376-88&amp;pmid=33940058&amp;doi=10.1016/j.jconrel.2021.04.036&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30. <span class="mixed-citation">
Deng L, Liang H, Burnette B, et al.. <span class="ref-title">Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice</span>. <span class="ref-journal">J Clin Invest</span>
2014;<span class="ref-vol">124</span>:687&#x02013;95. 10.1172/JCI67313
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3904601/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24382348" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1172%2FJCI67313" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Invest&amp;title=Irradiation+and+anti-PD-L1+treatment+synergistically+promote+antitumor+immunity+in+mice&amp;volume=124&amp;publication_year=2014&amp;pages=687-95&amp;pmid=24382348&amp;doi=10.1172/JCI67313&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31. <span class="mixed-citation">
Haslam A, Prasad V. <span class="ref-title">Estimation of the percentage of US patients with cancer who are eligible for and respond to Checkpoint inhibitor Immunotherapy drugs</span>. <span class="ref-journal">JAMA Netw Open</span>
2019;<span class="ref-vol">2</span>:e192535. 10.1001/jamanetworkopen.2019.2535
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6503493/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31050774" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1001%2Fjamanetworkopen.2019.2535" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA+Netw+Open&amp;title=Estimation+of+the+percentage+of+US+patients+with+cancer+who+are+eligible+for+and+respond+to+Checkpoint+inhibitor+Immunotherapy+drugs&amp;volume=2&amp;publication_year=2019&amp;pages=e192535&amp;pmid=31050774&amp;doi=10.1001/jamanetworkopen.2019.2535&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">32. <span class="mixed-citation">
Tseng D, Volkmer J-P, Willingham SB, et al.. <span class="ref-title">Anti-Cd47 antibody-mediated Phagocytosis of cancer by Macrophages primes an effective antitumor T-cell response</span>. <span class="ref-journal">Proc Natl Acad Sci U S A</span>
2013;<span class="ref-vol">110</span>:11103&#x02013;8. 10.1073/pnas.1305569110
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3703977/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23690610" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1073%2Fpnas.1305569110" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;title=Anti-Cd47+antibody-mediated+Phagocytosis+of+cancer+by+Macrophages+primes+an+effective+antitumor+T-cell+response&amp;volume=110&amp;publication_year=2013&amp;pages=11103-8&amp;pmid=23690610&amp;doi=10.1073/pnas.1305569110&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R33">33. <span class="mixed-citation">
Gordon SR, Maute RL, Dulken BW, et al.. <span class="ref-title">PD-1 expression by tumour-associated Macrophages inhibits Phagocytosis and tumour immunity</span>. <span class="ref-journal">Nature</span>
2017;<span class="ref-vol">545</span>:495&#x02013;9. 10.1038/nature22396
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5931375/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28514441" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnature22396" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=PD-1+expression+by+tumour-associated+Macrophages+inhibits+Phagocytosis+and+tumour+immunity&amp;volume=545&amp;publication_year=2017&amp;pages=495-9&amp;pmid=28514441&amp;doi=10.1038/nature22396&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R34">34. <span class="mixed-citation">
Hu Z, Li W, Chen S, et al.. <span class="ref-title">Design of a novel Chimeric peptide via dual blockade of Cd47/Sirpalpha and PD-1/PD-L1 for cancer Immunotherapy</span>. <span class="ref-journal">Sci China Life Sci</span>
2023. 10.1007/s11427-022-2285-6
 [<a href="https://pubmed.ncbi.nlm.nih.gov/37115491" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs11427-022-2285-6" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+China+Life+Sci&amp;title=Design+of+a+novel+Chimeric+peptide+via+dual+blockade+of+Cd47/Sirpalpha+and+PD-1/PD-L1+for+cancer+Immunotherapy&amp;publication_year=2023&amp;doi=10.1007/s11427-022-2285-6&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R35">35. <span class="mixed-citation">
Lee YH, Tai D, Yip C, et al.. <span class="ref-title">Combinational Immunotherapy for hepatocellular carcinoma: radiotherapy, immune Checkpoint blockade and beyond</span>. <span class="ref-journal">Front Immunol</span>
2020;<span class="ref-vol">11</span>:568759. 10.3389/fimmu.2020.568759
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7561368/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33117354" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffimmu.2020.568759" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Immunol&amp;title=Combinational+Immunotherapy+for+hepatocellular+carcinoma:+radiotherapy,+immune+Checkpoint+blockade+and+beyond&amp;volume=11&amp;publication_year=2020&amp;pages=568759&amp;pmid=33117354&amp;doi=10.3389/fimmu.2020.568759&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R36">36. <span class="mixed-citation">
Chen IX, Newcomer K, Pauken KE, et al.. <span class="ref-title">A bilateral tumor model identifies transcriptional programs associated with patient response to immune Checkpoint blockade</span>. <span class="ref-journal">Proc Natl Acad Sci USA</span>
2020;<span class="ref-vol">117</span>:23684&#x02013;94. 10.1073/pnas.2002806117
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7519254/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32907939" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1073%2Fpnas.2002806117" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+USA&amp;title=A+bilateral+tumor+model+identifies+transcriptional+programs+associated+with+patient+response+to+immune+Checkpoint+blockade&amp;volume=117&amp;publication_year=2020&amp;pages=23684-94&amp;pmid=32907939&amp;doi=10.1073/pnas.2002806117&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R37">37. <span class="mixed-citation">
Nishiga Y, Drainas AP, Baron M, et al.. <span class="ref-title">Radiotherapy in combination with Cd47 blockade elicits a macrophage-mediated Abscopal effect</span>. <span class="ref-journal">Nat Cancer</span>
2022;<span class="ref-vol">3</span>:1351&#x02013;66. 10.1038/s43018-022-00456-0
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9701141/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36411318" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs43018-022-00456-0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Cancer&amp;title=Radiotherapy+in+combination+with+Cd47+blockade+elicits+a+macrophage-mediated+Abscopal+effect&amp;volume=3&amp;publication_year=2022&amp;pages=1351-66&amp;pmid=36411318&amp;doi=10.1038/s43018-022-00456-0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R38">38. <span class="mixed-citation">
Yang X, Lu Y, Hang J, et al.. <span class="ref-title">Lactate-modulated immunosuppression of myeloid-derived Suppressor cells contributes to the Radioresistance of Pancreatic cancer</span>. <span class="ref-journal">Cancer Immunol Res</span>
2020;<span class="ref-vol">8</span>:1440&#x02013;51. 10.1158/2326-6066.CIR-20-0111
 [<a href="https://pubmed.ncbi.nlm.nih.gov/32917658" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F2326-6066.CIR-20-0111" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Immunol+Res&amp;title=Lactate-modulated+immunosuppression+of+myeloid-derived+Suppressor+cells+contributes+to+the+Radioresistance+of+Pancreatic+cancer&amp;volume=8&amp;publication_year=2020&amp;pages=1440-51&amp;pmid=32917658&amp;doi=10.1158/2326-6066.CIR-20-0111&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R39">39. <span class="mixed-citation">
Bronte V, Brandau S, Chen S-H, et al.. <span class="ref-title">Recommendations for myeloid-derived Suppressor cell nomenclature and characterization standards</span>. <span class="ref-journal">Nat Commun</span>
2016;<span class="ref-vol">7</span>:12150. 10.1038/ncomms12150
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4935811/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27381735" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fncomms12150" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Commun&amp;title=Recommendations+for+myeloid-derived+Suppressor+cell+nomenclature+and+characterization+standards&amp;volume=7&amp;publication_year=2016&amp;pages=12150&amp;pmid=27381735&amp;doi=10.1038/ncomms12150&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R40">40. <span class="mixed-citation">
Kim K, Skora AD, Li Z, et al.. <span class="ref-title">Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells</span>. <span class="ref-journal">Proc Natl Acad Sci USA</span>
2014;<span class="ref-vol">111</span>:11774&#x02013;9. 10.1073/pnas.1410626111
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4136565/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25071169" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1073%2Fpnas.1410626111" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+USA&amp;title=Eradication+of+metastatic+mouse+cancers+resistant+to+immune+checkpoint+blockade+by+suppression+of+myeloid-derived+cells&amp;volume=111&amp;publication_year=2014&amp;pages=11774-9&amp;pmid=25071169&amp;doi=10.1073/pnas.1410626111&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R41">41. <span class="mixed-citation">
Davis RJ, Silvin C, Allen CT. <span class="ref-title">Avoiding Phagocytosis-related Artifact in myeloid derived Suppressor cell T-lymphocyte suppression assays</span>. <span class="ref-journal">J Immunol Methods</span>
2017;<span class="ref-vol">440</span>:12&#x02013;8. 10.1016/j.jim.2016.11.006
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5186333/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27856191" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.jim.2016.11.006" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol+Methods&amp;title=Avoiding+Phagocytosis-related+Artifact+in+myeloid+derived+Suppressor+cell+T-lymphocyte+suppression+assays&amp;volume=440&amp;publication_year=2017&amp;pages=12-8&amp;pmid=27856191&amp;doi=10.1016/j.jim.2016.11.006&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R42">42. <span class="mixed-citation">
Hlavaty SI, Chang Y-M, Orth RP, et al.. <span class="ref-title">Bacterial killing activity of Polymorphonuclear myeloid-derived Suppressor cells isolated from tumor-bearing dogs</span>. <span class="ref-journal">Front Immunol</span>
2019;<span class="ref-vol">10</span>:2371. 10.3389/fimmu.2019.02371
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6795752/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31649676" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffimmu.2019.02371" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Immunol&amp;title=Bacterial+killing+activity+of+Polymorphonuclear+myeloid-derived+Suppressor+cells+isolated+from+tumor-bearing+dogs&amp;volume=10&amp;publication_year=2019&amp;pages=2371&amp;pmid=31649676&amp;doi=10.3389/fimmu.2019.02371&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R43">43. <span class="mixed-citation">
Gabrilovich D. <span class="ref-title">Mechanisms and functional significance of tumour-induced Dendritic-cell defects</span>. <span class="ref-journal">Nat Rev Immunol</span>
2004;<span class="ref-vol">4</span>:941&#x02013;52. 10.1038/nri1498
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15573129" ref="reftype=pubmed&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnri1498" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Immunol&amp;title=Mechanisms+and+functional+significance+of+tumour-induced+Dendritic-cell+defects&amp;volume=4&amp;publication_year=2004&amp;pages=941-52&amp;pmid=15573129&amp;doi=10.1038/nri1498&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10314633&amp;issue-id=437840&amp;journal-id=2348&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">Journal for Immunotherapy of Cancer</span> are provided here courtesy of <strong>BMJ Publishing Group</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC10314633/pdf/jitc-2023-007068.pdf" class="int-view">PDF (8.5M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/10314633/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/10314633/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="10314633" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10314633%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="xgPgzFJ5jLIHgr1cgpewlum0hvZJjSig1kEtaM3g9sLbIS6ktpp51Wm23mej3j5A">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10314633%2F&amp;text=Original%20research%3A%20Discovery%20of%20a%20novel%20dual-targeting%20D-peptide%20to%20block%20CD24%2FSiglec-10%20and%20PD-1%2FPD-L1%20interaction%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10314633%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314633/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC10314633/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/37344099/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC10314633/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/37344099/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC10314633/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/10314633/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC10314633/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
